



HAL
open science

Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy

Boris Gaillard, Cendrine Seguin, Jean-serge Remy, Françoise Pons, Luc Lebeau

► **To cite this version:**

Boris Gaillard, Cendrine Seguin, Jean-serge Remy, Françoise Pons, Luc Lebeau. Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy. *Chemistry - A European Journal*, 2019, 25 (68), pp.15662-15679. 10.1002/chem.201903976 . hal-02361375

HAL Id: hal-02361375

<https://hal.science/hal-02361375>

Submitted on 25 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy

Boris Gaillard, Cendrine Seguin, Jean-Serge Remy, Françoise Pons, and Luc Lebeau ^{*[a]}

Abstract: Sixteen cationic prodrugs of the antitumor alkylphospholipid (APL) erufosine were rationally synthesized to provide original gene delivery reagents with improved cytotoxicity profile. The DNA complexation properties of these cationic lipids were determined and associated transfection rates were measured. Besides, the self-assembly properties of the pro-erufosine compounds were investigated and their critical aggregation concentration was determined. Their hydrolytic stability under pH conditions mimicking the extracellular environment and the late endosome milieu was measured. Hemolytic activity and cytotoxicity of the compounds were investigated. The results obtained in various cell lines demonstrate that the prodrugs of erufosine display antineoplastic activity similar to that of the parent antitumor drug but are not associated with hemolytic toxicity, a dose-limiting side effect of APLs and a major obstacle to their use in anticancer therapeutic regimen. Furthermore, using lipoplexes prepared from a prodrug of erufosine and a plasmid DNA encoding a pro-apoptotic protein (TRAIL), evidence was provided for selective cytotoxicity towards tumor cells while non-tumor cells were resistant. This study demonstrates that the combination approach involving well tolerated erufosine cationic prodrugs and cancer gene therapy holds significant promise in tumor therapy.

Introduction

Alkylphospholipids (APLs) constitute a new class of antitumor drugs which do not interact directly with DNA but target the cell membrane where they accumulate and interfere with lipid metabolism and signaling pathways, thereby affecting the growth, cell cycle progression, and survival of tumor cells.^[1] APLs originally derived from lysophosphatidylcholines (lysoPCs),^[2] endogenous cell membrane components that result from hydrolysis of phosphatidylcholines (PCs) by phospholipases. Since lysoPCs are not stable and become inactivated, either by

the action of acyltransferase into PCs, or by lysophospholipases into glycerophosphocholine, efforts have been devoted to the synthesis of metabolically stable analogs to act as modulators of signaling pathways and alter biochemical routes (Figure 1). Edelfosine (1-O-octadecyl-2-O-methyl-*rac*-glycero-3-phosphocholine), the first molecule of this drug class was described in the late 60s.^[3] Though it was proven effective in *in vitro* and *in vivo* antiproliferative assays, clinical use was limited mainly due to metabolic instability, high hemolytic activity, and gastrointestinal toxicity.^[4] Ilmofosine (1-hexadecylthio-2-methoxymethyl-*rac*-glycero-3-phosphocholine), a thio-ether analog was proposed but, although it revealed as an effective inhibitor of cell proliferation, the chemical modification did not alter significantly its metabolic stability or cytotoxic effect.^[5] In the late 80s, miltefosine (HePC, hexadecylphosphocholine), a new analog lacking the glycerol moiety, was discovered and brought APLs to a clinical important level.^[6] Similarly to the earlier APLs, miltefosine presented appreciable *in vitro* antiproliferative activity but was found highly hemolytic and provoked marked gastrointestinal toxicity. Consequently, the clinical use of miltefosine has been limited mainly to the topical treatment of skin metastases in patients with breast cancer. To improve the therapeutic potency of APLs, replacement of the choline moiety in miltefosine by a dimethyl piperidinium group resulted in perifosine (octadecyl-1-(dimethylpiperidinio-4-yl)-phosphate).^[7] Stability and half-life of the compound were significantly increased, preventing rapid metabolic degradation.^[8] However, hemolytic activity still was high and toxicity profile after oral administration was similar to that of miltefosine with no successful outcome in the treatment of various




Figure 1. Structure of 18:0 lysoPC and APLs.

[a] Dr. B. Gaillard, C. Seguin, Dr. J.-S. Remy, Prof. Dr. F. Pons, Dr. L. Lebeau
Laboratoire de Conception et Application de Molécules Bioactives
UMR 7199 CNRS - Université de Strasbourg
Faculté de Pharmacie, 74 route du Rhin - BP 60024
67401 Illkirch (France)
E-mail: llebeau@unistra.fr

Supporting information for this article is given via a link at the end of the document.

cancers.^[9] As a member of the fourth generation of APLs, erufosine (erucylphosphohomocholine) resulted from the simultaneous introduction of an ω -9-*cis*-unsaturated alkyl chain with 22 carbon atoms and a homocholine moiety on the phosphate group of the APL. Extension of the hydrophobic chain decreased aqueous solubility of the molecule that likely self-assembles into lamellar structures instead of micelles, as was claimed for a closely related structural analog.^[10] As a consequence, the hemolytic potential was significantly reduced, which enabled intravenous (iv) administration that was not feasible with previous APLs.^[11]

Due to their particular mechanism of action targeting the cell membrane, APLs may be useful in combination with other chemotherapy agents and radiation therapy. Several clinical studies have reported significant benefits of combining APLs with diverse antineoplastic agents (cytarabine, gemcitabine, capecitabine, idarubicin, doxorubicin, etoposide, docetaxel, staurosporine, sorafenib, lenalidomide-dexamethasone, bortezomib-dexamethasone, temsirolimus...^[12] Besides, some of the pathways by which APLs lead to cytotoxicity have been shown to influence radiosensitivity or radioresistance of tumor cells, which resulted in successful clinical outcome of the combination of APLs with radiotherapy.^[13] On the other hand, there are only very few reports on the combination of APLs with cancer gene therapy. In 2003, Zeisig *et al.* described gene transfer with liposomal formulations incorporating APLs as helper lipids,^[14] assuming that APLs may promote the transmembrane transport of the plasmid-lipid complex (lipoplex) into the target cell due to their "detergent-like properties". Introduction of 2 % tetradecylphosphocholine (TPC), a lower carbon homologue of miltefosine, in the lipoplexes improved transfer efficiency of the LacZ gene into HCT15 and HCT116 human colon carcinoma cells up to 43 %. Similarly, Settelen *et al.* reported the intratumoral co-administration of naked DNA with miltefosine.^[15] Though this non-condensing-plasmid formulation failed to promote transgene expression *in vitro*, it showed a ten-fold increased reporter gene expression with increasing miltefosine concentration in Renca tumor following intratumor injection, as compared to plasmid alone. More recently, perfosine was used in combination with siRNA lipoplexes silencing c-FLIP, an inhibitory protein that blocks the extrinsic pathway of apoptosis by preventing caspase-8 activation by death receptors.^[16]

In the course of our research towards developing new nucleic acid carriers, we were attracted by APLs as they can be conveniently transformed into cationic lipids, *i.e.*, molecules that may be potentially powerful nucleic acid condensing reagents. Therefore, the transformation of an APL into a phosphotriester derivative generates a net positive charge on the molecule. This derivative can thus establish electrostatic interactions with negatively charged nucleic acid and promote its condensation into discrete particles as required for cell uptake and intracellular delivery through endocytosis.^[17] Furthermore, when the transformation of the APL compound is reversible and sensitive, *e.g.*, to a pH or enzyme stimulus as met along the endo-lysosome pathway, *in situ* regeneration of the zwitterionic APL may be expected. Intermolecular electrostatic interaction between the ammonium headgroup of the newly unmasked APL molecule and

nucleic acid phosphates then becomes thermodynamically disfavored, as compared to intramolecular zwitterionic interaction. This process thus triggers and facilitates nucleic acid decondensation, which is required for nucleic acid processing by the cell translation machinery. Besides, from the sorting endosomes, most amphiphilic molecules enter the endocytic recycling pathway.^[18] Lipid recycling at the plasma membrane is a highly dynamic and effective process,^[19] and antiproliferative APL produced *in situ* from the nucleic acid carrier is prone to trafficking at the plasma membrane where it can operate intrinsic apoptotic activity.^[20] Starting from erufosine, one of the most promising APLs to date, original lipid constructs were thus imagined for simultaneously implementing gene therapy and chemotherapy. A series of 16 biolabile cationic lipids have been designed which can regenerate erufosine *in situ* under a chemical or enzyme stimulus. The properties of these erufosine prodrugs as gene delivery reagents have been investigated using a luciferase reporter gene assay, and their intrinsic cytotoxicity has been determined. Finally, using a plasmid DNA encoding the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), the *in vitro* synergistic antiproliferative effect of TRAIL and erufosine prodrugs has been examined.

Results and Discussion

Design of erufosine prodrugs as gene carriers

Erufosine is currently the most promising APL, essentially due to its structure with a 22-carbon long chain and an ω -9-*cis*-double bond that imposes formation of lamellar instead of micellar structures in aqueous solution. This results in a significant decrease in hemolytic activity as compared to other APLs and allows intravenous administration at clinically relevant high doses.^[21] Transformation of erufosine into a cationic species with nucleic acid complexation ability can be straightforwardly achieved through esterification into phosphotriester compounds. However, non-selective hydrolysis of such compounds into phosphodiester would produce a mixture of erufosine together with two other phosphodiester resulting from the alternate leaving of the homocholine or heneicosenol phosphate substituent. Consequently, to favor formation of the parent APL upon hydrolysis of these phosphotriesters, it is valuable to introduce a (bio)labile substituent at the phosphate that may be preferentially removed under a chemical or enzyme stimulus. Based on previous reports on the development of DOPC-based phosphoacetals as labile cationic lipids for gene delivery,^[22] we aimed to extend this methodology to produce potent prodrugs of erufosine (Figure 2). Consequently, erufosine was derivatized to incorporate various *n*-carbon alkyl chains connected to the phosphate group, directly or through a mixed acetal moiety. Compounds were developed both in the ester (compounds noted E_{En}) and carbonate (compounds noted E_{Cn}) mixed phosphoacetal series to modulate their hydrolytic stability which presumably at least partly determines their potency as gene delivery reagents and the rate of erufosine release *in situ*. Pursuing the same idea, a methyl substituent was introduced on the acetal bridge (compounds noted $E_{E,n}$ and $E_{C,n}$) as it was recently demonstrated




Figure 2. Synthetic route to and structure of the 16 erufosine prodrugs investigated in this work.

that it can significantly improve the hydrolysis rate of phosphoacetal compounds.^[22] All these compounds were produced according to the same protocol, reacting erufosine with a large excess of electrophilic reagent (8 eq.) in boiling anhydrous chloroform for 24 h. The reaction yields were highly variable (6 to 97 %) and did depend on the reactivity of the electrophilic reagents and on the stability of the reaction products, especially for compound **E₂**. Due to the presence of two stereogenic centers, compounds displaying a methyl-substituted acetal bridge (**E_{E'12}**, **E_{C'12}**, **E_{E'18:1}**, and **E_{C'18:1}**) were produced as a mixture of four diastereomers. When possible, the couples of enantiomers were separated for analytic purpose, but evaluations (*vide infra*) were performed on the original mixture of the four isomers.

Hydrolytic stability of the erufosine prodrugs

Aqueous formulation of the erufosine prodrugs results in the formation of nanosized lipid aggregates that most likely are internalized by cells through the endocytic route. To express the expected intrinsic antitumor activity (*vide infra*), these compounds need to be transformed back into erufosine which is the bioactive species. Hydrolysis of the erufosine prodrugs may occur under a chemical stimulus, e.g., acidification of the environment as observed in the endosome during its maturation process, or may be under the control of hydrolytic enzymes that are abundantly introduced into the endosome compartment upon fusion with lysosomes. To get an insight into regeneration of erufosine from its prodrugs, we determined the hydrolytic stability of the pro-erufosine compounds under pH conditions mimicking the

extracellular and late endosome environment, *i.e.*, pH 7.4 and 4.5, respectively. This was achieved through ³¹P-NMR measurements. As phosphotriesters and phosphodiester display ³¹P chemical shifts differing by *ca.* 5–6 ppm, it is possible to precisely monitor the quantity of both species in a sample and thus determine the hydrolysis rate of a phosphotriester in solution. The pro-APLs were formulated into liposomes by using an injection technique,^[23] at pH 7.4 and 4.5, and incubated at 25 °C. Periodical acquisition of the ³¹P-NMR spectra using a 4-sec pulse cycle (enabling for quantitative determination of the phosphorylated species through the integration of their resonance signal) was carried out and the rate of hydrolysis was determined (Table 1). Whatever the compound investigated, only one single ³¹P resonance did appear during the course of the experiments. This signal did correspond to that of erufosine and no other phosphodiester could be detected. This confirmed that hydrolysis selectively occurred at the phosphoacetal center. Consistently, phosphotriester **E₁₂** lacking acetal moiety revealed fully stable both under neutral and acidic conditions, even after an incubation period of 31 days. All the other erufosine derivatives were sensitive to hydrolysis. As a general trend, hydrolysis was quicker at pH 7.4 than at pH 4.5. This indicates that mixed acetals of carboxylic or carbonic and phosphoric esters display a reactivity that is different from that of dialkyl acetals which are highly labile species in acidic media, and is consistent with results reported for other phosphoacetals.^[22e, f]

Table 1. Hydrolytic stability of the pro-erufosine compounds. Compounds formulated into liposomes were incubated at 25 °C and hydrolysis at pH 7.4 and 4.5 was monitored by quantitative ³¹P-NMR measurements. H₁₂₀ refers to the extent of hydrolysis (%) after incubation over 120 h. When possible, time required for 50 % hydrolysis (*t*_{1/2}) was calculated from the theoretical curve fitting with the experimental data.

Entry	Compound	H ₁₂₀ (%)		<i>t</i> _{1/2} (h)	
		pH 7.4	pH 4.5	pH 7.4	pH 4.5
1	E ₁₂ ^[a]	0	0	–	–
2	E _{E12}	14	2	–	–
3	E _{E'12}	56	53	96	100
4	E _{C12}	8	1	–	–
5	E _{C'12}	6	5	–	–
6	E _{E18:1}	23	18	–	–
7	E _{E'18:1}	56	54	96	104
8	E _{C18:1}	10	0	–	–
9	E _{C'18:1}	4	6	–	–
10	E _{E2}	–	–	–	–
11	E _{E6}	18	8	–	–
12	E _{E8}	16	1	–	–
13	E _{E10}	16	2	–	–
14	E _{E14}	14	2	–	–
15	E _{E16}	16	2	–	–
16	E _{E18}	14	3	–	–

[a] No hydrolysis was observed after an incubation period of 31 days.

Based on these former reports, introduction of a methyl substituent on the acetal bridge was expected to improve the hydrolysis rate of the erufosine prodrugs. This however only held true in the ester series and E_{E12} and $E_{E18:1}$ indeed hydrolyzed faster than E_{E12} and $E_{E18:1}$, respectively. In the carbonate series, compounds were significantly more resistant to hydrolysis and introduction of a methyl substituent on the acetal bridge had only little effect, if any, on the rate of the hydrolytic reaction (E_{C12} vs. E_{C12} , and $E_{C18:1}$ vs. $E_{C18:1}$). With regards to the influence of the length of the pendant arm tethered to erufosine through the acetal linker on the hydrolysis rate, no significant difference was observed, except for E_{E6} that revealed *ca.* four times more labile than higher homologs under acidic conditions. For technical reasons, we could not measure the hydrolytic stability of the lower homolog E_{E2} . Though these results allowed a comparison of the hydrolytic stability of the erufosine prodrugs, it must be kept in mind that it only projected an incomplete and truncated image of the *in cellulo* stability of these compounds, as *in situ* enzymatic hydrolysis of the pro-erufosine compounds most probably occurs much faster than "purely" pH-controlled chemical hydrolysis, as was reported with other phosphoacetals.^[22c]

Lipoplex formation and characterization

The ability of the erufosine prodrugs to interact electrostatically with nucleic acids and form complexes was studied by conventional electrophoretic DNA retardation assay, in which a full retard of plasmid DNA (pDNA) is observed at a lipid/pDNA phosphate ratio (N/P) corresponding to electroneutrality of the complexes. The erufosine prodrugs generally led to a full pDNA complexation at N/P > 1.2-2.0 as illustrated for compound E_{E12} in Figure 3. In the case of E_{E2} however, electroneutrality was not reached even at N/P 4, presumably because this compound was too labile (*vide supra*) and was partly hydrolyzed during gel migration. The size (hydrodynamic diameter) and charge (zeta potential, ζ) of the lipoplexes prepared at a N/P ratio of 3 with one molar equivalent of DOPE were investigated by DLS (Table 2). Most lipoplexes displayed a size in the range of 100-150 nm. Noteworthy, introduction of an unsaturated chain on the phosphate group of erufosine, regardless of the linker, translated into the formation of significantly larger lipoplexes (250-600 nm, entry 6-9). As could be expected considering electrophoretic behavior, nearly all lipoplexes were highly positively charged at N/P 3, ζ values ranging from +36 to +54 mV. Again, E_{E2} -based




Figure 3. pDNA binding ability of pro-erufosine E_{E12} at increasing N/P ratio (0 to 4). Lipoplexes were prepared by mixing 0.8 μ g of plasmid DNA (pCMV-Gluc) and increasing amounts of pro-erufosine in 10 mM Hepes buffer. After an incubation period of 20 min, samples (25 μ L) were analyzed by 1% agarose gel electrophoresis using Tris-acetate-EDTA buffer. DNA was visualized after ethidium bromide staining.

Table 2. Particle size and zeta potential (ζ) of lipoplexes obtained from pro-erufosine compounds and pCMV-Gluc, as measured by dynamic light scattering. Lipoplexes were prepared at 25 °C, in 5% glucose, at a N/P ratio of 3 and with 1 molar equivalent of DOPE. Data are the mean of three independent measurements (\pm SD).

Entry	Compound	Particle size (nm)	ζ (mV)
1	E_{E12}	194 \pm 28	+ 42 \pm 1
2	E_{E12}	141 \pm 5	+ 48 \pm 2
3	E_{E12}	149 \pm 15	+ 39 \pm 2
4	E_{C12}	117 \pm 15	+ 40 \pm 1
5	E_{C12}	92 \pm 10	+ 54 \pm 2
6	$E_{E18:1}$	263 \pm 9	- 35 \pm 4
7	$E_{E18:1}$	597 \pm 19	+ 45 \pm 2
8	$E_{C18:1}$	611 \pm 12	+ 47 \pm 3
9	$E_{C18:1}$	608 \pm 44	+ 44 \pm 1
10	E_{E2}	133 \pm 10	- 31 \pm 2
11	E_{E6}	144 \pm 31	+ 47 \pm 6
12	E_{E8}	110 \pm 4	+ 36 \pm 1
13	E_{E10}	122 \pm 11	+ 41 \pm 3
14	E_{E14}	121 \pm 29	+ 41 \pm 1
15	E_{E16}	138 \pm 29	+ 42 \pm 3
16	E_{E18}	120 \pm 19	+ 43 \pm 1

lipoplexes distinguished as they were negatively charged, which was consistent with significant hydrolysis of the compound in aqueous media. More intriguing was the negative charge measured for lipoplexes prepared from $E_{E18:1}$ (-35 mV \pm 4 mV), revealing significant differences in the organization of the lipid molecules and pDNA within the transfection particles (affecting a more precise matching of the ammonium and phosphate species^[24]), as compared to those obtained with other lipids, especially $E_{E18:1}$, $E_{C18:1}$ and $E_{C18:1}$.

DNA transfection

The efficacy of the pro-erufosine compounds to deliver a plasmid DNA intracellularly was investigated in the A549 cell line using the reporter gene pCMV-Gluc encoding the *Gaussia princeps* luciferase, under the control of a CMV promoter. As this luciferase is excreted by cells, transgene expression was directly assessed by standard bioluminescence measurements on cell culture supernatant. Various structural features of the pro-erufosine compounds were examined, in order to identify structure-activity relationships, namely the nature of the biolabile linker (acetal of esters and acetal of carbonates), presence of a substituent on the acetal bridge, and length of the carbon chain introduced on the erufosine phosphate group.

Nature of the biolabile linker

Considering a fixed-length substituent (C_{12}) at the phosphate group of erufosine, the five pro-erufosine compounds E_{E12} , E_{E12} , E_{E12} , E_{C12} , and E_{C12} were compared in order to investigate the influence of the nature of the biolabile linker on transfection efficiency (Figure 4). No significant transgene expression was




Figure 4. Transfection profile of pro-erufosine compounds as a function of the structure of the biolabile linker installed on the phosphate group. Experiments were carried out on A549 cells, varying the amount of DOPE in the lipid formulations and the charge ratio N/P (DNA: 0.4 μ g/well), in the presence of 10 % serum. Control (C) refers to basal bioluminescence measured in untreated cells. Lipofectamine[®]-based lipoplexes (L) were prepared under experimental conditions that were optimized according to the supplier's instructions. Data shown are representative of a triplicate determination (mean \pm SD).

generally observed in the absence of DOPE, a fusogenic helper lipid routinely used in transfection experiments.^[25] Formulations incorporating up to three molar equivalents of DOPE were systematically evaluated, and one molar equivalent of the fusogenic lipid with respect to the pro-erufosine compound most often led to optimal transfection efficiency. With regards to the chemical nature of the linker installed between the phosphate group of erufosine and the C₁₂ carbon chain (*i.e.*, docecyl or dodecanoyl substituent), acetal ester (E_{E12}) revealed more efficient to deliver the pCMV-Gluc transgene to cells and was almost matching the results obtained with Lipofectamine[®] 2000, a gold standard gene delivery reagent. Transfection rate was increased by a *ca.* twenty-fold factor, as compared to that of E₁₂ lacking specific biolabile linker. Replacement of the ester by a carbonate (*i.e.*, E_{C12})

resulted in a two- to three-fold decrease in transfection efficiency. Besides, introduction of a methyl substituent on the acetal bridge also translated into a loss of transgene expression. The effect was more pronounced in the ester series (8.5 10^{10} vs. 1.1 10^{10} RLU/mg protein for E_{E12} and E_{E12}, resp.) than in the carbonate series (3.3 10^{10} vs. 1.5 10^{10} RLU/mg protein for E_{C12} and E_{C12}, resp.). Thus, it was deduced that acceleration of pro-erufosine hydrolysis was not in favor of a higher transfection rate. This might indicate either that some early decondensation of plasmid in the extracellular milieu decreased cell uptake or that intracellular plasmid decondensation was not achieved in a timely manner, possibly resulting in enhanced DNA degradation by nucleases before reaching the nucleus for processing.

Considering the compound series displaying an unsaturated $C_{18:1}$ pendant arm (*i.e.*, $E_{E18:1}$, $E_{E'18:1}$, $E_{C18:1}$, and $E_{C'18:1}$), results were slightly different (Figure S1). Whereas optimum transfection rate required the use of one molar equivalent of DOPE or more with $E_{E18:1}$, $E_{C18:1}$, and $E_{C'18:1}$, this lipid "helper" was deleterious with $E_{E'18:1}$, decreasing transfection rate by *ca.* an order of magnitude. With respect to the nature of the biolabile linker, introduction of a methyl substituent on the acetal bridge in the ester series slightly improved transfection efficiency ($E_{E18:1}$ vs. $E_{E'18:1}$), whereas opposite effect was observed in the carbonate series ($E_{C18:1}$ vs. $E_{C'18:1}$). Together with the results obtained in the C_{12} series, this highlighted that transfection rate did depend both on the structure of the biolabile linker and on that of the pendant alkyl chain. One hypothesis is that conformation and orientation of the polar head of the molecules facing the aqueous milieu depend on intrinsic structural parameters of the lipid (structure of the pendant hydrophobic arm, nature of the linker, steric hindrance at the acetal bridge...), with direct implications on lipase activity with cascading effects (modification of the hydrolysis rate of the compounds, of pDNA decondensation rate under the threat of nucleases, and ultimately of transfection efficiency).

Lipoplexes of large size are frequently reported to be more effective to promote *in vitro* transgene expression than smaller ones due to sedimentation and facilitated size-dependent cellular uptake *via* a switch from a clathrin-dependent to a caveolae-mediated cell entry pathway.^[26] That was not the case in this study as larger lipoplexes (*i.e.* from $E_{E18:1}$, $E_{E'18:1}$, $E_{C18:1}$, and $E_{C'18:1}$, with size ranging from 263 to 608 nm) revealed less efficient than smaller ones (*i.e.* from E_{E12} , $E_{E'12}$, E_{C12} , and $E_{C'12}$, with size ranging from 92 to 149 nm). Similar results for cationic lipids such as SAINTS^[27] or COPA^[28] have been reported previously. In our study, that probably revealed that due the structure of the pro-erufosine they were made of, and although internalized by cells to a lesser extent, the smaller lipoplexes were more timely processed in the intracellular compartment.

Influence of the carbon chain length

Selecting the acetal ester backbone for further structural optimization, systematic variation of the length of the alkyl chain tethered to the biolabile acetal moiety, from 2 to 18 carbon atoms, was realized for investigating its influence on gene delivery properties (Figure 5). Transfection rate clearly depended on alkyl chain length, high transgene expression being obtained provided the alkyl chain contained more than 2 and less than 18 carbon atoms. Results distributed in a quasi-bell-shaped curve, with maximum efficiency attained with the dodecanoyl chain (E_{E12}). Compound with the shorter chain (E_{E2}) failed to mediate high transgene expression, maybe in relation to the lack of stability of the compound already aforementioned. At the opposite, degraded transfection rate was observed for compounds with alkyl chains beyond C_{16} (E_{E18}), which was yet exacerbated by the presence of an unsaturation in the chain ($E_{E18:1}$). Similar results were obtained in the 16HBE cell line (Figure S2). In this case, degradation of the transfection rate with E_{E2} and $E_{E18:1}$ was even more marked, which confirmed the deleterious effect of the introduction of a short or unsaturated chain on the carrier backbone.




Figure 5. Transfection profile of pro-erufosine E_{En} compounds as a function of the length of the alkyl chain tethered to the phosphate group. Experiments were carried out on A549 cells, in the presence of 10 % serum. Lipoplexes were formulated with DOPE (1 eq.) at N/P 3 (DNA: 0.4 μ g/well). Control (C) refers to basal bioluminescence measured in untreated cells. Data shown are representative of a triplicate determination (mean \pm SD).

DNA dose and N/P ratio

As an important parameter governing transgene expression, we then investigated the influence of the pDNA dose deposited onto the cultured cells. A549 cells were treated with increasing amounts of pCMV-Gluc (from 0.1 to 0.4 μ g/well) formulated into lipoplexes (E_{E12} /DOPE 1/1) with gradual increase of the N/P ratio (1 to 4). As a general trend and as might be expected, the higher the DNA dose, the higher the transfection rate (Figure 6). However, when increasing the pDNA dose, optimum transfection efficiency was attained at lower N/P ratio. Indeed, at the lower pDNA dose (0.1 μ g/well), transfection rate did not yet reach a maximum with N/P increasing up to 4. At 0.2 μ g DNA/well, maximum transfection efficiency was attained at N/P ratio of 3-4, whereas it was observed at N/P of 2.75-3 at 0.3 μ g/well and at N/P of 2.5-2.75 at 0.4 μ g/well. This shift of charge ratio for optimal transfection may be consistently explained by intrinsic cytotoxicity of the DNA carrier (*vide infra*).

Serum compatibility

A serious limitation of the cationic lipid-mediated gene delivery is that transfection efficiency is drastically decreased in the presence of serum proteins. This likely results from the formation of the so-called "biocorona" that anionic proteins and other serum components (fatty acids, heparin...) form around the cationic transfection particles, provoking their destabilization and/or stifling their cell uptake and endosome escape. Although some formulations remain efficient at the level of serum content typically used in cell culture (\leq 10 %), the effect of higher serum levels has been scarcely investigated in prior studies.^[29] To gain an insight into the effect of serum on the intracellular delivery of pDNA by erufosine prodrugs, E_{E12} /DOPE/pCMV-Gluc lipoplexes (1 equiv. DOPE, N/P 3) were incubated with cells in the presence of an increasing concentration of serum, from 10 to 75 % (Figure 7). Considering the lower DNA dose (0.2 μ g/well), transfection rate was decreased by *ca.* two orders of magnitude as serum content increased from 10 to 25 %, and in 50 % serum (that roughly corresponds to concentration in blood), no transgene expression was detected. When a higher DNA dose (0.4 μ g/well) was deposited onto the cells,




Figure 6. Rate of transfection mediated by pro-erufosine E_{E12} at various charge ratios (N/P varying from 1 to 4), with increasing dose of pCMV-Gluc (0.1, 0.2, 0.3, and 0.4 $\mu\text{g}/\text{well}$, from light blue to dark blue, resp.). Experiments were carried out on A549 cells, in the presence of serum (10 %). Lipoplexes were formulated with DOPE (1 eq.) and control (C) refers to basal bioluminescence measured in untreated cells. Data shown are representative of a triplicate determination (mean \pm SD).




Figure 7. Transfection efficiency as a function of serum content for $E_{E12}/\text{DOPE}/\text{pCMV-Gluc}$. Lipoplexes were prepared with DOPE (1 equiv.) at N/P 3. Experiments were carried out on A549 cells (6,000 cells/well) and cell supernatant (containing 10 % serum) was replaced with culture medium complemented with 10, 25, 50, and 75 % serum just before adding the lipoplexes (0.2 and 0.4 μg of plasmid per well; light blue and dark blue bars, resp.). Control (grey bars) refers to basal bioluminescence measured in untreated cells. Data shown are representative of a triplicate determination (mean \pm SD). Statistically significant differences when compared to untreated cells are indicated: *** $p < 0.001$, ** $p < 0.01$, or * $p < 0.05$.

deleterious effect of serum was counteracted and significant luciferase production still was measured in 50 % serum.

Intrinsic antitumor activity

Pro-erufosine compounds have been designed so they may be hydrolyzed *in situ* under a pH or enzymatic stimulus into erufosine, a compound with intrinsic antitumor activity. In order to characterize the antineoplastic effect of the pro-erufosine compounds, we investigated their physical properties, hemolytic activity, intrinsic cytotoxicity, and combined antitumor activity when used as a carrier for intracellular delivery of a plasmid DNA encoding a proapoptotic protein.

Self-assembly properties of the erufosine prodrugs

Alkylphospholipids are membrane-active compounds that can disrupt phospholipid bilayers. They can thus interfere with biological membranes delimitating the cellular and intracellular

compartments which makes them key players in various membrane signaling pathways involved in carcinogenesis.^[1c] In the absence of serum, the lytic concentration for different APLs has been shown to reflect their critical micellar concentration (CMC) which are in the low μM range.^[30] We thus determined the CMC for erufosine and for the pro-erufosine compounds using the fluorescent probe technique that has been extensively applied to study surfactant micellization. Noteworthy, due to tethering of an "additional" hydrophobic moiety to the erufosine scaffold, pro-erufosine compounds display a lower hydrophilic-lipophilic balance (HLB) than their parent compound and most likely preferentially form lamellar structures in aqueous environment. Consequently, the term critical aggregation concentration (CAC) is suggested in place of CMC.^[31] In this study, pyrene was selected as the hydrophobic fluorescent dye. Fluorescence of pyrene is sensitive to the polarity of the solubilizing medium and the dye exhibits different fluorescence behaviors in hydrophilic and lipophilic environments. Measurements were performed in water and data obtained for erufosine and its prodrugs are collected in Table 3. The CAC value measured for erufosine was

Table 3. Critical aggregation concentration of erufosine and its prodrugs as measured with pyrene by the fluorescent probe technique.

Entry	Compound	CAC (μM)	Entry	Compound	CAC (μM)
1	E	1.6 ± 0.5	10	E_{E12}	0.7 ± 0.3
2	E_{E2}	7.7 ± 2.1	11	E_{E12}	0.6 ± 0.2
3	E_{E6}	1.1 ± 0.7	12	E_{E'12}	1.1 ± 0.7
4	E_{E8}	1.0 ± 0.3	13	E_{C12}	1.1 ± 0.2
5	E_{E10}	0.8 ± 0.5	14	E_{C'12}	0.9 ± 0.2
6	E_{E12}	0.6 ± 0.2	15	E_{E18:1}	0.9 ± 0.6
7	E_{E14}	1.2 ± 0.3	16	E_{E'18:1}	1.0 ± 0.6
8	E_{E16}	1.3 ± 0.4	17	E_{C18:1}	0.8 ± 0.4
9	E_{E18}	1.4 ± 0.7	18	E_{C'18:1}	0.6 ± 0.2

FULL PAPER

1.56 ± 0.47 μM and no earlier data was found in the literature. Interestingly, CMC values below 10 nM have been suggested for erucylphosphocholine (ErPC), an erufosine homolog compound.^[32] It cannot be excluded that replacement of the ethylene group with a propylene one between the phosphate and ammonium moieties can have an effect on the solvation state of the zwitterionic head group of the lipid and, consequently, on the CMC of the compound. However, if such an effect has been already reported, e.g., for hexadecylphosphocholine (miltefosine) and hexadecylphosphohomocholine (with CMC values of 13 and 20 μM, resp.),^[33] it was of lower magnitude. As expected, transformation of erufosine into pro-erufosine compounds through the replacement of the phosphate negative charge by a hydrophobic substituent translated into a decrease in the CAC values. This was not the case however for **E_{E2}**. The reason for this is unclear. It might be proposed that the introduction of an acetoxymethyl substituent (a short polyoxygenated group that can establish hydrogen bonds with water molecules) on the phosphate group of erufosine did not much change the global hydrophobicity of the molecule while better complexation of the trimethylammonium moiety by water molecules (as compared to zwitterion) did enhance hydrophilicity of the polar head group, thus improving aqueous solubility of the compound. CAC slightly decreased with alkyl chain elongation up to C₁₂, then a reverse effect was observed up to C₁₈ (Figure S3). This however must be considered with caution, as standard deviations in CAC measurements were significant. For the same reason, no trend could be detected with respect to the structure of the biolabile spacer (*i.e.*, ester vs. carbonate and non-substituted vs. substituted acetal), or to the introduction of an unsaturation in the C₁₈ chain. Differences were small and getting a deeper understanding of the structure-property relationships would require a more precise determination of the CAC values.

Hemolytic activity

Hemolytic activity is associated with most of the antitumor APLs described to date, so these compounds are not compatible with intravenous administration.^[30a] When APLs are used in liposomal formulations (e.g., co-formulated with cholesterol and 1,2-dipalmitoyl-*sn*-glycero-phosphoglycerol), lysis of red blood cells can be partly prevented.^[34] This however is accompanied by a significant reduction in the antitumor activity of the compound, as previously shown *in vitro*.^[35] In serum-free conditions, the lytic concentration for various APLs and related compounds generally corresponds well to their CMC.^[30] Decreasing the CMC of APLs through their reversible transformation into more hydrophobic derivatives should thus result in increasing their biocompatibility. To investigate this point, the hemolytic activity of erufosine and pro-erufosine compounds was determined using an erythrocyte leakage assay. Sheep red blood cells (RBC) were treated with increasing amounts of aqueous dispersion of the compounds at 37 °C and hemolysis (hemoglobin leakage) was monitored spectrophotometrically. First, we investigated the hemolytic effect of erufosine over an incubation period of 1 h. As expected, damage to the RBC increased with the APL concentration. The concentration provoking 50 % hemolysis (HC₅₀) was around 130 μM and 84.9 ± 4.6 % hemolysis was achieved at 200 μM (HA₂₀₀) (Table 4 and Figure S4). Under the same incubation conditions, hemolytic

Table 4. Hemolytic activity of erufosine and pro-erufosine compounds upon incubation with sheep RBC for 1 and 24 h at 37 °C.

Entry	Compound	1 h		24 h	
		HC ₅₀ (μM)	HA ₂₀₀ (%)	HC ₅₀ (μM)	HA ₂₀₀ (%)
1	E	130	84.9 ± 4.6	–	–
2	E_{E6}	–	25.0 ± 0.3	140	85.2 ± 6.2
3	E_{I2}	–	0.5 ± 0.4	–	12.0 ± 1.9
4	E_{E12}	–	< 0.5	–	18.6 ± 1.5
5	E_{E'12}	–	< 0.5	–	8.7 ± 1.1
6	E_{C12}	–	< 0.5	–	9.6 ± 2.3
7	E_{C'12}	–	0.7 ± 0.2	–	7.3 ± 0.8
8	E_{E18}	–	< 0.5	–	11.3 ± 4.0
9	E_{E18:1}	–	1.0 ± 0.3	–	1.2 ± 0.7

[a] Concentration of compound inducing 50 % hemolysis. [b] Percentage of hemolysis provoked by the compound at the higher concentration tested (200 μmol).

effect of most of the pro-erufosine compounds was below a measurable amount (< 1 %) except for **E_{E6}** (HA₂₀₀: 25.0 ± 0.3). In order to better characterize the pro-erufosine compounds, the hemolytic effect of two pro-erufosine compounds was measured over extended periods of time (Figure 8 and Figure S5–S6). As might be expected, hemolysis increased with time and reached significant values after 18–24 h. Consequently, a 24-h incubation time was chosen in the following evaluations so as to discriminate against the pro-APLs (Figure S7). Even under these tough incubation conditions, the pro-erufosine compounds revealed only slightly harmful to RBC, with HA₂₀₀ values below 20 % (Table 4). Again, **E_{E6}** stood as an exception displaying a HA₂₀₀ value of 85.2 ± 6.2 %, whereas HC₅₀ was around 140 μM. At the opposite, no general trend was observed with regards to the structure of the biolabile linker, and lower hydrolytic stability did not systematically translate into higher hemolytic effect.




Figure 8. Time course of hemolytic activity of pro-erufosine **EE12** (■) and **E12** (▲). Sheep RBC were incubated at 37 °C with 200 μM of the compounds.

Considering these data, it was concluded that the transformation of erufosine into prodrugs drastically reduces the hemolytic activity, which makes the pro-erufosine compounds highly compatible with intravenous administration.

Cytotoxic effect

The intrinsic cytotoxicity of APLs is not strictly related to their ability to permeabilize membranes and lyse cells. It is widely assumed that, at pharmacologically relevant concentration, APLs insert into the cell membrane, provoking a biophysical disturbance through altered cholesterol homeostasis, and perturbing various signal transduction pathways.^[1c] In order to estimate the antiproliferative potency of the pro-erufosine compounds, a dose-response study was conducted in three human pulmonary cell lines: A549 (alveolar carcinoma epithelial cells), H292 (carcinoma mucoepidermoid cells), and 16HBE (bronchial epithelial cells). Thirteen pro-erufosine compounds were tested in parallel with parent erufosine. Cells were exposed for 24 h to concentration of lipids between 500 nM and 1 mM, and cell survival was determined using the MTT assay.^[36] For the three cell lines, a concentration dependent decrease in cell viability was seen in response to erufosine and pro-erufosine compounds (Figure S8-S10). Interpolated from the experimental concentration–effect curves, the IC₅₀ values (concentration that inhibited the cell growth by 50 %) reflecting the cytotoxicity of the compounds are presented in Table 5. The three cell lines showed varying sensitivities to the compounds. The IC₅₀ values ranged from 57 to 199 μM for A549 cells, from 43 to 174 μM for H292 cells, and from 19 to 257 μM for non-cancerous 16HBE cells. Cytotoxicity of the erufosine prodrugs did not parallel their hydrolytic stability as determined by ³¹P-NMR measurements in an "enzyme-free" model aqueous medium (*vide supra*). This likely originates from the *in situ* enzymatic hydrolysis of the pro-APLs compounds in the complemented culture medium which competes with pure pH-controlled chemical hydrolysis. Depending on the pro-APL, its structure and the nature of the substituent installed on the phosphate group, the compound may or not be a substrate for some specific lipases and, thus, may or may not be metabolized into parent cytotoxic erufosine. However, all the pro-erufosine compounds displayed marked cytotoxicity that roughly compared to that of erufosine (*i.e.*, with IC₅₀ in the low μM range), revealing that they were productively metabolized into erufosine, though not at the same rate. It is noteworthy that **E_{E2}** that distinguished by lower chemical stability as compared to the other pro-erufosine compounds (*vide supra*) was among the less cytotoxic prodrugs in the series, with IC₅₀ values that were three to ten times higher than that of erufosine, depending on the cell line. Considering the prodrugs in the ester series (**E_{E_n}**) and except for **E_{E2}** (*vide supra*), a general trend was that the IC₅₀ value steadily increased with the length of the pendant arm tethered to erufosine (*i.e.*, with *n*), up to C₁₆. A longer chain (*i.e.*, C₁₈) tended to decrease the IC₅₀ value, and unsaturation in the C₁₈ chain further enhanced this fall. These effects were marked in the A549 cell line (Figure S11), and the same trends were identified in the H292 and 16HBE cell lines, although all the compounds in these series have not been systematically assayed. Finally, with regard to the aggregation properties of the compounds, no relationship could

Table 5. Antitumor activity (IC₅₀) of erufosine and pro-erufosine compounds in various cell lines exposed for 24 h at 37 °C, as measured by MTT dye reduction assay.

Entry	Compound	IC ₅₀ (μM)		
		A549	H292	16HBE
1	E	57 ± 8	46 ± 8	19 ± 3
2	E_{E2}	171 ± 44	174 ± 39	208 ± 66
3	E_{E6}	60 ± 8	43 ± 7	58 ± 14
4	E_{E8}	88 ± 10	–	–
5	E_{E10}	136 ± 40	–	–
6	E_{E12}	81 ± 7	124 ± 11	225 ± 31
7	E_{E12}	151 ± 42	125 ± 26	144 ± 66
8	E_{E12}	192 ± 44	73 ± 15	63 ± 7
9	E_{C12}	161 ± 21	167 ± 56	252 ± 112
10	E_{C12}	179 ± 63	161 ± 25	257 ± 81
11	E_{E14}	193 ± 59	–	–
12	E_{E16}	199 ± 30	–	–
13	E_{E18}	170 ± 72	141 ± 49	165 ± 63
14	E_{E18:1}	97 ± 35	61 ± 20	–

be established between CAC and IC₅₀ values, thus confirming that the cytotoxic effect of erufosine and pro-erufosine compounds was not achieved through their membrane disrupting properties.

Combined antitumor activity of TRAIL and erufosine prodrugs

The use of combination therapy for cancer treatment is well established.^[37] Indeed, single-agent therapy aims to suspend one signaling pathway and cancer cells can thrive through the initial oncogenic route and activate another parallel signaling pathway.^[38] Multi-agent therapy can simultaneously modulate several signaling pathways in diseased cells, maximizing the therapeutic effect and, possibly, overcoming resistance mechanisms. Whereas chemotherapy drugs are normally associated with severe side-effects, administration of a combination of agents hitting various targets in different pathways and displaying different toxicity profiles can improve the therapeutic index, either in the form of better efficacy, or in the form of comparable efficacy and reduced toxicity. In recent years, combination anticancer therapy between nucleic acids and small-molecule drugs has been recommended for cancer treatment because of such advantages and because it can serve to overcome genetic heterogeneity and existence of complicated signaling pathways.^[39] Besides, compared with coordinate treatment with two drugs in separated carriers, the co-delivery of two agents in one single carrier may allow resolving the

complexity of variation in pharmacokinetics and ensures the co-localization of the two agents to maximize the additive or synergistic effect, thereby reducing the amount of each drug and promoting the efficacy of the combination therapy.^[40] Our hypothesis herein was that the combination of pro-APLs and pDNA encoding a pro-apoptotic protein would diminish tumor cell survival and show at least an additive antineoplastic effect.

Therefore, in order to investigate antitumor effect of the pro-erufosine compounds as both gene delivery reagents and prodrugs of antiproliferative erufosine, a plasmid DNA encoding the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, also called Apo2L or TNFSF10) was selected. As a member of the tumor necrosis factor (TNF) superfamily, TRAIL can induce apoptosis in malignant tumors while sparing normal cells.^[41] In humans, TRAIL activates extrinsic apoptotic pathway after binding TRAIL death receptors (DRs), TRAIL-R1 (DR4, TNFRSF10A) and TRAIL-R2 (DR5, TNFRSF10B), and TRAIL decoy receptors that do not possess functional death domain, TRAIL-R3 (DcR1, TNFRSF10C) and TRAIL-R4 (DcR2, TNFRSF10D). Like most TNF superfamily members, TRAIL is a homotrimeric, type II transmembrane protein. It can thus simultaneously recruit several receptors. If the recruited receptors are all death receptors (*i.e.*, DR4 or DR5), a death-inducing signaling complex (DISC) is formed that can strongly activate various caspases inducing apoptosis. At the opposite, recruitment of inhibitor receptors (*i.e.*, DcR1 or DcR2) leads to a DISC that cannot or only weakly activate caspases and therefore impairs TRAIL-induced cell death.^[42] Nevertheless, the situation may be further complicated by the cell-type dependency of the apoptotic response, itself influenced by the effect on ligand binding mode of factors such as the level of TRAIL oligomerization or glycosylation.^[43]

Characterization of TRAIL receptor expression and activity in the different cell lines

Characterization of the expression and activity of the TRAIL receptors in the different cell lines was a prerequisite to validate the cell models suitable for evaluation of combined antitumor activity of TRAIL and erufosine prodrugs. Expression of the TRAIL receptors was assessed by flow cytometry (Figure 9). Death receptors TRAIL-R1 and TRAIL-R2 were expressed in the three cell lines in similar amounts, except for TRAIL-R1 which expression was significantly higher in A549 cells. TRAIL-R3 was expressed only in H292 and 16HBE cells while TRAIL-R4 was not expressed in any cell line. The sensitivity of the three cell lines to TRAIL was then checked using SuperKillerTRAIL® (SPK), a hexameric TRAIL recombinant protein providing significantly enhanced apoptosis.^[44] Cells were incubated with SPK for 24 h and cell viability was subsequently measured (Figure S12). SPK induced apoptosis of H292 and 16HBE cells in a dose-dependent manner, with EC₅₀ of 0.49 ± 0.18 and 0.68 ± 0.39 nM, respectively (*i.e.*, 12.7 ± 4.7 and 17.6 ± 10.2 ng/mL). Noteworthy, the EC₅₀ value for SPK in H292 cancer cells was significantly lower than that reported for TRAIL (25 ± 5 ng/mL)^[45] which is consistent with the hexameric structure of SPK. Sensitivity of the non-tumor 16HBE cells to TRAIL was unexpected and revealed that recombinant SPK may not reflect properly all the properties of monomeric TRAIL. By contrast, only low induction of apoptosis

was observed in A549 cells, since cell viability still was higher than 70 % at the SPK dose of 200 ng/mL. Once again these data are consistent with those in the literature (IC₅₀ > 1500 ng/mL).^[45] Taken together, these results suggest that induction of apoptosis in the three cell models using a plasmid DNA encoding TRAIL should be feasible, though A549 cells that expressed the higher level of TRAIL-R1 appeared unexpectedly less sensitive to SPK than H292 and 16HBE cells.




Figure 9. Expression of the TRAIL receptors in the three cell lines as monitored by flow cytometry. The fluorescence histograms were obtained using PE-conjugated antibodies.

Combined cytotoxic activity

Pro-erufosine **E**_{E12} was selected as the best pro-erufosine candidate for the following experiments. The three cell lines were treated for 24 h with lipoplexes prepared with either pCMV-Gluc or pUNO1-hTRAIL, a plasmid DNA encoding TRAIL. The transfection particles were prepared with one equivalent of DOPE at a charge ratio of 3, corresponding to the previously established optimized conditions (*vide supra*). The dose of pDNA applied to the cells was varied from 0.1 to 0.4 µg DNA per well and incubation was carried out for 24 h. For comparison, Lipofectamine® was assayed in parallel.

Luciferase expression was determined in the three cell lines, and A549 and H292 cells displayed very similar expression profiles (Figure S13). On the other hand, 16HBE cells revealed a little bit less responsive, since **E**_{E12}-mediated transgene expression was approximately four times weaker in this cell line, while remaining at the higher rate with Lipofectamine®. In any case, the transfection rate in the three cell lines was highly significant, suggesting that replacing pCMV-Gluc with pUNO1-hTRAIL should give rise to significant expression of TRAIL.

Cell viability was monitored in the three cell lines treated with pCMV-Gluc and pUNO1-hTRAIL (Figure 10). Control experiments with Lipofectamine® revealed no decrease in cell viability using pUNO1-hTRAIL as compared to pCMV-Gluc. Although this could indicate that no functional TRAIL was produced, it is worth noting




Figure 10. Antiproliferative effect of lipoplexes prepared from E_{E12} or Lipofectamine® 2000 (L), and pCMV-Gluc (light blue and white bars, resp.) or pUNO1-hTRAIL (dark blue and black bars, resp.) on three cell lines. Pro-erufosine-based lipoplexes were formulated with DOPE (1 eq.) at N/P 3, with a pDNA dose varying from 0.1 to 0.4 $\mu\text{g}/\text{well}$. Lipofectamine-based lipoplexes (0.1 μg plasmid/well) were prepared according to the optimized experimental conditions provided by the supplier. Cell viability was measured by MTT assay. Data shown are representative of a triplicate determination (mean \pm SD). Statistically significant differences are indicated: *** $p < 0.001$, ** $p < 0.01$, or * $p < 0.05$.

that intrinsic cytotoxicity of this transfection reagent was basically very high both in A549 and H292 cells (with less than 40–50 % cell survival), and thus could mask some effect of TRAIL. In the non-tumor 16HBE cell line, no such intrinsic cytotoxicity of Lipofectamine® could be invoked (~20 %), but data were consistent with the resistance of non-tumor cells to TRAIL.^[46] With regards to the pro-erufosine pDNA delivery reagent E_{E12} , statistically significant enhancement of cytotoxicity was observed with pUNO1-hTRAIL, as compared to pCMV-Gluc, in A549 and H292 cells, but not in 16HBE cells. This effect was clearly visible from the intermediate plasmid dose of 0.2 ng/mL and indicated that the transgene product was indeed functional and did express intrinsic antineoplastic effect in the two tumor cell lines. Resistance of the non-tumor 16HBE cells to TRAIL again was consistent with results in the literature. Finally, the combination of pro-erufosine compound E_{E12} and pUNO1-hTRAIL induced death of A549 and H292 tumor cells selectively (cell death > 40–50 %) while preserving normal 16HBE cells (cell death < 20–25 %). Extensive work now is required on various testing platforms to determine whether there is synergism between the pro-erufosine compound and pUNO1-hTRAIL or simply additive anticancer effect, and identify optimal dose combination as certain dose ratios of combined drugs can be synergistic, while other ratios may be antagonistic.^[47]

Conclusion

In the present study, we designed and optimized cationic prodrugs of erufosine, and investigated their properties as both gene delivery reagents and antineoplastic drugs. We demonstrated that these pro-erufosine compounds can efficiently deliver plasmid DNA to mammal cells and that those incorporating a pH- or enzyme-specific cleavage site were invariably more potent—at least by an order of magnitude—than an analog compound lacking such specific cleavage site. These results thus demonstrate the superiority of biolabile lipids bearing transient

cationic charge in DNA delivery experiments. We also showed that these gene carriers are further degraded into parent antitumor erufosine and thus express intrinsic antitumor properties but are not associated with any hemolytic effect, as is the case for erufosine. Finally, using a plasmid DNA encoding the pro-apoptotic protein TRAIL, we evidenced selective toxicity towards tumor cells while non-tumor cells were resistant. Together, it appears that the combination approach involving well tolerated erufosine cationic prodrugs and cancer gene therapy holds significant promise and, e.g., might be useful in the management of some drug-resistant tumors.

Experimental Section

Materials

Unless otherwise stated, all chemical reagents were purchased from Alfa Aesar (Bischoff, France) and used without purification. When required, solvents were dried just before use as described elsewhere.^[48] Thin layer chromatography (TLC) was performed on pre-coated plates (0.25 mm Silica Gel 60, F₂₅₄, Merck, Darmstadt, Germany). Products were purified by flash chromatography over silica gel (Silica Gel 60, 40–63 μm , Merck, Darmstadt, Germany). NMR spectra were recorded on Bruker 400 MHz Avance III instrument. ¹H-, ¹³C-, and ³¹P-NMR chemical shifts δ are reported in ppm relative to their standard reference (¹H: CHCl₃ at 7.27 ppm, CD₂HOD at 3.31 ppm; ¹³C: CDCl₃ at 77.0 ppm, CD₃OD at 49.0 ppm; ³¹P: (MeO)₂P(O)Me at 38.78 ppm). IR spectra were recorded on a FT-IR Nicolet 380 spectrometer in the ATR mode and absorption values ν are in wave numbers (cm⁻¹). Mass Spectra (MS) were recorded on an Agilent Technologies 6520 Accurate Mass QToF instrument, using electrospray ionization (ESI) mode. Mass data are reported in mass units (m/z). 1,2-Dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE) was from Avanti Polar Lipids (Alabaster, USA). Lipofectamine® 2000 was obtained from Invitrogen (Cergy Pontoise, France). Plasmid pCMV-Gluc (5.7 kbp) and coelenterazine substrate for monitoring *Gaussia* luciferase activity were from Nanolight Technology (Pinetop, Az, USA). Plasmid pUNO1-hTRAIL (4026 bp) was from InvivoGen (Toulouse, France) and SuperKillerTRAIL® (SPK, 26 kDa) was from Enzo Life Sciences (Villeurbanne, France). PE-conjugated anti-TRAIL antibodies used in flow cytometry analysis were from Diaclone (Besançon, France). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was from Sigma-Aldrich (Saint-Quentin Fallavier, France). Culture media DMEM, DMEM/F12, RPMI, and supplements were from GIBCO-BRL (Cergy-Pontoise, France). Fetal calf serum (FCS) was from Perbio (Brebieres, France). A549 cells (human lung carcinoma; CCL-185), and NCI-H292 (H292) cells (human lung mucoepidermoid carcinoma; CRL-1848) were obtained from ATCC-LGC (Molsheim, France). The 16HBE14o- (16HBE) cells were a generous gift from Dr D. Gruenert (California Pacific Medical Center Research Institute, San Francisco, CA, USA). Defibrinated sheep blood was from Eurobio (Les Ulis, France).

Abbreviations: PE, petroleum ether; s, singlet; d, doublet; t, triplet; q, quadruplet; b, broad.

Synthesis

Erufosine (E). Triethylamine (1.30 mL, 9.27 mmol) was added dropwise to phosphorus oxychloride (288 μL , 3.09 mmol) in anhydrous CH₂Cl₂ (10 mL) at 0 °C under inert atmosphere. Then erucyl alcohol^[49] (1.00 g, 3.09 mmol) in CH₂Cl₂ (15 mL) was added dropwise over a 90-min period and the reaction mixture was allowed to warm to rt for 30 min, time after

which all the alcohol had reacted. Temperature was brought back to 0 °C and 1,3-propanediol (223 µL, 3.09 mmol) in CH₂Cl₂ (15 mL) was added dropwise within 60 min. The reaction mixture was stirred at rt for 16 h before quenching by addition of 10 % HCl (10 mL). It was extracted twice with CH₂Cl₂, and the organic layer was washed with brine, dried over MgSO₄, filtered, and reduced under vacuum. The crude residue was purified by flash chromatography (Et₂O) to yield 2-erucyloxy-1,3,2-dioxaphosphinane 2-oxide (0.82 g, 60 %). *R*_f: 0.30 (Et₂O). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.6 Hz, 3H); 1.26 (m, 30H); 1.61 and 1.77 (2 m, 1H); 1.72 (m, 2H); 2.00 (m, 4H); 2.26 (dt, *J*₁ = 15.3 Hz, *J*₂ = 10.3 Hz, *J*₃ = 5.3 Hz, 1H); 4.09 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 4.32–4.45 (m, 4H); 5.34 (m, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.9; 25.7; 26.4; 27.4 (2C); 29.4; 29.5 (3C); 29.7 (2C); 29.8 (4C); 30.0 (2C); 30.5; 32.1; 67.8; 68.6 (2C); 130.1 (2C). ³¹P-NMR (162 MHz, CDCl₃) δ –7.08. IR ν 457; 594; 721; 771; 828; 883; 934; 966; 1029; 1141; 1237; 1297; 1464; 2852; 2921.

The previous compound (200 mg, 0.45 mmol) in CHCl₃/CH₃CN/*i*-PrOH 3:5:5 (8 mL) was treated with 45 % (w/w) aqueous trimethylamine (3 mL, 20.2 mmol) at 70 °C. After 24 h, all starting material was consumed (checked by TLC). Volatile was removed under vacuum, the residue was extracted twice with CHCl₃/MeOH 9/1 and the organic layer was washed with brine, reduced under vacuum, diluted with CHCl₃, dried over MgSO₄, filtered and evaporated. The crude residue was purified by flash chromatography (CH₂Cl₂/MeOH/H₂O 75:22:3 to 45:45:10) to yield erufosine (123 mg, 75 %). *R*_f: 0.28 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.86 (t, *J* = 6.2 Hz, 3H); 1.25 (m, 30H); 1.60 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 2.00 (m, 4H); 2.04 (m, 2H); 3.11 (s, 9H); 3.47 (m, 2H); 3.82 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 3.90 (td, *J*₁ = *J*₂ = 6.1 Hz, 2H); 5.31 (m, 2H). ¹³C-NMR (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.3; 23.2; 25.1; 26.4; 27.7 (2C); 29.8 (2C); 29.9; 30.0; 30.1 (2C); 30.2 (4C); 30.3 (2C); 31.4; 32.4; 53.4 (3C); 61.9; 64.9; 66.2; 130.3 (2C). ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ +0.66. IR ν 528; 553; 721; 840; 945; 1059; 1092; 1223; 1466; 1480; 1640; 2850; 2919; 3271. HR-MS (ESI+) *m/z* [M+H]⁺ calcd for C₂₈H₅₉NO₄P⁺ 504.4176, found 504.4193.

Preparation of chloromethyl esters and 1-chloroethyl esters

Typical procedure: Chloromethyl dodecanoate. Dodecanoyl chloride (3.5 mL, 14.7 mmol) was added dropwise over 10 min to a mixture of anhydrous zinc chloride (45 mg, 0.29 mmol) and paraformaldehyde (663 mg, 22.1 mmol) at 0 °C under argon. After the addition was complete, the reaction mixture was stirred for 1 h at 0 °C, and allowed to warm to room temperature overnight. The crude mixture was directly purified by flash chromatography (PE/Et₂O 100:0 to 95:5) to provide chloromethyl dodecanoate (2.61 g, 71 %) as a colorless oil. *R*_f: 0.6 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.8 Hz, 3H); 1.26 (m, 16H); 1.65 (tt, *J*₁ = *J*₂ = 7.2 Hz, 2H); 2.38 (t, *J* = 7.5 Hz, 2H); 5.70 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 24.7; 29.1; 29.3; 29.5; 29.6; 29.7 (2C); 32.1; 34.2; 68.7; 171.8. IR ν 462; 718; 771; 1034; 1106; 1135; 1338; 1441; 1465; 1765; 2853; 2922.

1-Chloroethyl dodecanoate. Paraformaldehyde was replaced by acetaldehyde. Yield: 42 %. *R*_f: 0.6 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.7 Hz, 3H); 1.26 (m, 16H); 1.64 (tt, *J*₁ = *J*₂ = 7.3 Hz, 2H); 1.78 (d, *J* = 5.8 Hz, 3H); 2.34 (t, *J* = 7.5 Hz, 2H); 6.55 (q, *J* = 5.8 Hz, 1H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.9; 24.8; 25.4; 29.2; 29.4; 29.5; 29.6; 29.7; 29.8; 32.1; 34.4; 80.8; 171.8. IR ν 664; 721; 771; 934; 1019; 1084; 1110; 1142; 1219; 1272; 1378; 1465; 1760; 2853; 2923.

Chloromethyl acetate. Yield: 90 %. ¹H-NMR (400 MHz, CDCl₃) δ 2.14 (s, 3H); 5.68 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 20.8; 68.7; 172.0. IR ν 461; 598; 713; 818; 982; 1015; 1041; 1194; 1371; 1712; 1762.

Chloromethyl hexanoate. Yield: 77 %. *R*_f: 0.75 (PE/Et₂O 75:25). ¹H-NMR (400 MHz, CDCl₃) δ 0.90 (t, *J* = 6.6 Hz, 3H); 1.32 (m, 4H);

1.65 (tt, *J*₁ = *J*₂ = 7.2 Hz, 2H); 2.36 (t, *J* = 7.5 Hz, 2H); 5.68 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.1; 22.5; 24.4; 31.3; 34.2; 68.8; 172.0. IR ν 718; 773; 988; 1039; 1094; 1137; 1223; 1245; 1708; 1761; 2931; 2957.

Chloromethyl octanoate. Yield: 82 %. *R*_f: 0.75 (PE/Et₂O 90:10). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.6 Hz, 3H); 1.30 (m, 8H); 1.65 (tt, *J*₁ = *J*₂ = 7.2 Hz, 2H); 2.38 (t, *J* = 7.5 Hz, 2H); 5.68 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.2; 22.7; 24.7; 30.0 (2C); 31.7; 34.1; 68.7; 171.9. IR ν 462; 716; 1038; 1102; 1136; 1260; 1441; 1763; 2856; 2926.

Chloromethyl decanoate. Yield: 80 %. *R*_f: 0.75 (PE/Et₂O 90:10). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.8 Hz, 3H); 1.26 (m, 12H); 1.65 (tt, *J*₁ = *J*₂ = 7.3 Hz, 2H); 2.38 (t, *J* = 7.5 Hz, 2H); 5.70 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.9; 24.8; 29.2; 29.4 (2C); 29.6; 32.1; 34.2; 68.8; 172.0. IR ν 463; 718; 758; 1034; 1105; 1135; 1260; 1338; 1441; 1465; 1764; 2854; 2924.

Chloromethyl tetradecanoate. Yield: 68 %. *R*_f: 0.75 (PE/Et₂O 90:10). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.4 Hz, 3H); 1.26 (m, 20H); 1.65 (tt, *J*₁ = *J*₂ = 7.2 Hz, 2H); 2.38 (t, *J* = 7.5 Hz, 2H); 5.70 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 24.7; 29.1; 29.3; 29.5; 29.6; 29.7; 29.8 (3C); 32.1; 34.2; 68.7; 172.0. IR ν 463; 719; 758; 1036; 1108; 1135; 1217; 1340; 1441; 1465; 1765; 2853; 2922.

Chloromethyl hexadecanoate. Yield: 71 %. *R*_f: 0.75 (PE/Et₂O 90:10). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.8 Hz, 3H); 1.26 (m, 24H); 1.65 (tt, *J*₁ = *J*₂ = 7.2 Hz, 2H); 2.38 (t, *J* = 7.6 Hz, 2H); 5.70 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 24.7; 29.1; 29.3; 29.5; 29.6; 29.7; 29.8 (5C); 32.1; 34.2; 68.7; 171.9. IR ν 437; 686; 718; 772; 994; 1017; 1035; 1098; 1147; 1192; 1216; 1260; 1383; 1438; 1461; 1472; 1755; 2848; 2915; 2964.

Chloromethyl octadecanoate. Yield: 76 %. *R*_f: 0.6 (PE/Et₂O 90:10). ¹H-NMR (400 MHz, CDCl₃) δ 0.90 (t, *J* = 6.7 Hz, 3H); 1.32 (m, 28H); 1.65 (tt, *J*₁ = *J*₂ = 7.0 Hz, 2H); 2.36 (t, *J* = 7.5 Hz, 2H); 5.68 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 24.7; 29.1; 29.3; 29.5; 29.6; 29.7; 29.8 (7C); 32.1; 34.2; 68.7; 171.9. IR ν 686; 718; 793; 1017; 1035; 1045; 1099; 1147; 1191; 1259; 1383; 1438; 1462; 1472; 1755; 2848; 2916; 2959.

Chloromethyl oleate. Yield: 60 %. *R*_f: 0.5 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.7 Hz, 3H); 1.29 (m, 20H); 1.65 (tt, *J*₁ = *J*₂ = 7.1 Hz, 2H); 2.01 (m, 4H); 2.38 (t, *J* = 7.5 Hz, 2H); 5.34 (m, 2H); 5.70 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 24.7; 27.3 (2C); 29.1; 29.2 (2C); 29.5 (2C); 29.7; 29.8; 29.9; 32.1; 34.1; 68.7; 129.9; 130.2; 171.9. IR ν 462; 719; 771; 1036; 1093; 1114; 1219; 1260; 1338; 1440; 1463; 1766; 2853; 2922; 3003.

1-Chloroethyl oleate. Paraformaldehyde was replaced by acetaldehyde. Yield: 27 %. *R*_f: 0.5 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.7 Hz, 3H); 1.28 (m, 20H); 1.64 (tt, *J*₁ = *J*₂ = 7.1 Hz, 2H); 1.78 (d, *J* = 5.8 Hz, 3H); 2.01 (m, 4H); 2.34 (t, *J* = 7.5 Hz, 2H); 5.34 (m, 2H); 6.55 (q, *J* = 5.8 Hz, 1H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 24.7; 25.4; 27.4 (2C); 29.1; 29.2 (2C); 29.5 (2C); 29.7; 29.8; 29.9; 32.1; 34.3; 80.7; 129.9; 130.2; 171.6. IR ν 666; 721; 772; 934; 1019; 1083; 1137; 1220; 1272; 1378; 1463; 1761; 2853; 2922; 3004.

Preparation of chloromethyl carbonates and 1-chloroethyl carbonates

Typical procedure: Chloromethyl dodecyl carbonate. To a solution of dodecanol (3.02 g, 16.2 mmol) and anhydrous Et₃N (4.5 mL, 32.0 mmol) in Et₂O (35 mL) at 0 °C under argon, chloromethylchloroformate (2.2 mL, 24.7 mmol) in anhydrous Et₂O (10 mL) was added dropwise over 15 min. The resulting mixture was warmed to rt and stirred for 2 h. Precipitate was

discarded by filtration and the filtrate was reduced under vacuum. The crude residue was purified by flash column chromatography over silica gel (PE/Et₂O 100:0 to 95:5) to yield chloromethyl dodecyl carbonate (2.60 g, 58 %) as a clear oil. TLC *R_f* 0.50 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.7 Hz, 3H); 1.26 (m, 18H); 1.70 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 4.22 (t, *J* = 6.7 Hz, 2H); 5.73 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.9; 25.8; 28.7; 29.3; 29.5; 29.6; 29.7; 29.8 (2C); 32.1; 69.6; 72.3; 153.6. IR ν 718; 787; 961; 1113; 1239; 1343; 1443; 1765; 2853; 2922.

1-Chloroethyl dodecyl carbonate. Chloromethyl chloroformate was replaced by 1-chloroethyl chloroformate. Yield: 58 %. *R_f*: 0.6 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.8 Hz, 3H); 1.26 (m, 18H); 1.68 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 1.83 (d, *J* = 5.8 Hz, 3H); 4.20 (t, *J* = 6.7 Hz, 2H); 6.43 (q, *J* = 5.8 Hz, 1H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.9; 25.4; 25.8; 28.7; 29.3; 29.5; 29.6; 29.7; 29.8 (2C); 32.1; 69.3; 84.7; 153.1. IR ν 662; 785; 892; 1008; 1067; 1111; 1243; 1348; 1385; 1466; 1762; 2853; 2923.

Chloromethyl oleyl carbonate. Yield: 80 %. *R_f*: 0.6 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.7 Hz, 3H); 1.28 (m, 22H); 1.69 (tt, *J*₁ = *J*₂ = 7.0 Hz, 2H); 2.01 (m, 4H); 4.22 (t, *J* = 6.8 Hz, 2H); 5.34 (m, 2H); 5.72 (s, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 25.7; 27.4 (2C); 28.6; 29.3 (2C); 29.5 (2C); 29.7 (2C); 29.8; 29.9; 31.9; 69.5; 72.3; 129.9; 130.2; 153.6. IR ν 719; 759; 787; 965; 1114; 1243; 1343; 1443; 1766; 2853; 2922; 3004.

1-Chloroethyl oleyl carbonate. Chloromethyl chloroformate was replaced by 1-chloroethyl chloroformate. Yield: 85 %. *R_f*: 0.6 (PE/Et₂O 95:5). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.7 Hz, 3H); 1.29 (m, 22H); 1.69 (tt, *J*₁ = *J*₂ = 7.0 Hz, 2H); 1.83 (d, *J* = 5.8 Hz, 3H); 2.01 (m, 4H); 4.20 (t, *J* = 6.8 Hz, 2H); 5.34 (m, 2H); 6.43 (q, *J* = 5.8 Hz, 1H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.3; 22.8; 25.4; 25.8; 27.4 (2C); 28.7; 29.3 (2C); 29.5 (2C); 29.7; 29.9 (3C); 31.9; 69.3; 84.6; 129.9; 130.2; 153.1. IR ν 663; 722; 758; 894; 1008; 1111; 1245; 1348; 1384; 1464; 1763; 2853; 2922; 3004.

Preparation of erufosine prodrugs

General procedure. Electrophilic reagent (4.0 mmol) and erufosine (0.5 mmol) were reacted in refluxing anhydrous CHCl₃ (12 mL) for 24 h with stirring under inert atmosphere. The solvent was removed under vacuum and the crude residue was purified by flash chromatography (CH₂Cl₂/MeOH 10:0 to 7:3) to yield the corresponding pro-erufosine.

3-(((Dodecyl)oxy)(erucyloxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium triflate (E₁₂**).** Compound **E₁₂** (139 mg, 97 %) was obtained from erufosine (102 mg, 0.16 mmol) and dodecyl triflate^[50] (170 mg, 0.53 mmol) according to the general procedure except the reaction was conducted at rt. *R_f*: 0.7 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, *J* = 6.6 Hz, 6H); 1.26 (m, 48H); 1.67 (tt, *J*₁ = *J*₂ = 6.8 Hz, 4H); 2.02 (m, 4H); 2.20 (m, 2H); 3.24 (s, 9H); 3.55 (m, 2H); 4.04 (td, *J*₁ = *J*₂ = 6.8 Hz, 4H); 4.14 (td, *J*₁ = *J*₂ = 6.8 Hz, 2H); 5.35 (m, 2H). ¹³C-NMR (100.7 MHz, CDCl₃) δ 14.4 (2C); 22.8 (2C); 24.5; 25.6 (2C); 27.4 (2C); 29.3 (2C); 29.5 (4C); 29.8 (5C); 29.9 (5C); 30.0 (2C); 30.4 (2C); 32.1 (2C); 53.6 (3C); 63.8; 64.1; 68.5; 68.6; 130.0; 130.1. ³¹P-NMR δ (162 MHz, CDCl₃) δ - 1.43. IR ν 516; 572; 638; 772; 866; 1030; 1158; 1225; 1257; 1465; 2852; 2921; 3500. HR-MS (ESI⁺) *m/z* [M-CI]⁺ calcd for C₄₀H₈₃NO₄P⁺ 672.6054, found 672.6039.

3-(((Dodecanoyl)oxy)methoxy)(erucyloxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (E_{E12}**).** Compound **E_{E12}** (124 mg, 41 %) was obtained from erufosine (201 mg, 0.40 mmol) and chloromethyl dodecanoate (791 mg, 3.17 mmol) according to the general procedure. *R_f*: 0.5 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1)

δ 0.86 (t, *J* = 6.8 Hz, 6H); 1.25 (m, 46H); 1.63 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 1.68 (tt, *J*₁ = *J*₂ = 7.4 Hz, 2H); 1.99 (m, 4H); 2.19 (m, 2H); 2.40 (t, *J* = 7.5 Hz, 2H); 3.16 (s, 9H); 3.49 (m, 2H); 4.07 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 4.17 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 5.31 (m, 2H); 5.62 (ABX syst., *J*_{AB} = 5.2 Hz, *J*_{AX} = 13.4 Hz, *J*_{BX} = 11.4 Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.5 (2C); 23.3 (2C); 24.8; 25.3; 26.1; 27.8 (2C); 29.7; 29.8; 30.0 (5C); 30.2; 30.3 (6C); 30.4 (2C); 30.5 (2C); 30.9; 32.6 (2C); 34.6; 53.7 (3C); 64.3; 65.5; 69.9; 83.5; 130.5; 130.6; 173.2. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ - 3.38. IR ν 491; 721; 757; 858; 968; 1029; 1116; 1157; 1261; 1466; 1760; 2850; 2919; 2956; 3389. HR-MS (ESI⁺) *m/z* [M-CI]⁺ calcd for C₄₁H₈₃NO₆P⁺ 716.5953, found 716.5954.

3-(((1-(Dodecanoyloxy)ethoxy)(erucyloxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (E_{E12}**).** Compound **E_{E12}** (152 mg, 50 %) was obtained as a mixture of four diastereomers from erufosine (201 mg, 0.40 mmol) and 1-chloroethyl dodecanoate (841 mg, 3.20 mmol) according to the general procedure. *R_f*: 0.4 and 0.5 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.86 (t, *J* = 6.8 Hz, 6H); 1.25 (m, 46H); 1.56 (d, *J* = 5.2 Hz, 3H); 1.63 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 1.68 (tt, *J*₁ = *J*₂ = 7.4 Hz, 2H); 1.99 (m, 4H); 2.19 (m, 2H); 2.36 (t, *J* = 7.4 Hz, 2H); 3.17 (s, 9H); 3.52 (m, 2H); 4.07 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 4.17 (m, 2H); 5.30 (m, 2H); 6.44 (qd, *J*₁ = *J*₂ = 5.2 Hz, 1H). ¹³C-NMR (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.4 (2C); 21.7; 23.3 (2C); 24.8; 25.3; 26.1; 27.8 (2C); 29.7; 29.8; 30.0 (5C); 30.2 (4C); 30.3 (5C); 30.4 (2C); 30.9; 32.6 (2C); 34.7; 53.7 (3C); 64.3; 65.2; 69.6; 92.0; 130.5 (2C); 173.7. ³¹P-NMR δ (162 MHz, CD₃OD/CDCl₃ 1:1) δ - 5.15 and - 5.85. IR ν 515; 721; 850; 969; 1041; 1090; 1167; 1269; 1379; 1466; 1753; 2850; 2919; 3388. HR-MS (ESI⁺) *m/z* [M-CI]⁺ calcd for C₄₂H₈₅NO₆P⁺ 730.6109, found 730.6120.

3-((((Dodecyl)oxy)carbonyl)oxy)methoxy)(erucyloxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (E_{C12}**).** Compound **E_{C12}** (97 mg, 31 %) was obtained from erufosine (200 mg, 0.40 mmol) and chloromethyl dodecyl carbonate (884 mg, 3.17 mmol) according to the general procedure. *R_f*: 0.45 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.88 (t, *J* = 6.6 Hz, 6H); 1.27 (m, 48H); 1.68 (m, 4H); 2.00 (m, 4H); 2.21 (m, 2H); 3.17 (s, 9H); 3.50 (m, 2H); 4.10 (td, *J*₁ = *J*₂ = 6.8 Hz, 2H); 4.17 (t, *J* = 6.4 Hz, 2H); 4.25 (m, 2H); 5.32 (m, 2H); 5.65 (m, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.6 (2C); 23.6 (2C); 25.0; 26.3; 26.6; 28.0 (2C); 29.5; 30.1; 30.2 (2C); 30.3 (2C); 30.4; 30.5 (4C); 30.6 (6C); 30.7 (2C); 31.1; 32.8 (2C); 53.8 (3C); 64.5; 65.9; 70.2 (2C); 86.8; 130.7; 130.7; 156.0. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ - 3.06. IR ν 490; 721; 790; 860; 946; 1024; 1115; 1257; 1466; 1761; 2852; 2920; 3399. HR-MS (ESI⁺) *m/z* [M-CI]⁺ calcd for C₄₂H₈₅NO₇P⁺ 746.6058, found 746.6069.

3-(((1-((((Dodecyl)oxy)carbonyl)oxy)ethoxy))(erucyloxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (E_{C12}**).** Compound **E_{C12}** (128 mg, 41 %) was obtained as a mixture of four diastereomers from erufosine (199 mg, 0.39 mmol) and 1-chloroethyl dodecyl carbonate (923 mg, 3.15 mmol) according to the general procedure. *R_f*: 0.45 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.86 (t, *J* = 6.8 Hz, 6H); 1.25 (m, 48H); 1.59 (d, *J* = 5.2 Hz, 3H); 1.67 (m, 4H); 2.00 (m, 4H); 2.19 (m, 2H); 3.17 (s, 9H); 3.50 (m, 2H); 4.07 (m, 2H); 4.16 (m, 2H); 4.20 (m, 2H); 5.30 (m, 2H); 6.34 (m, 1H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.6 (2C); 21.5; 23.6 (2C); 25.0; 26.3; 26.6; 28.0 (2C); 29.5; 29.9 (3C); 30.0 (3C); 30.2 (2C); 30.3 (2C); 30.4 (6C); 30.5 (2C); 30.8; 32.6 (2C); 53.7 (3C); 64.3; 65.3; 69.8 (2C); 95.5; 130.5 (2C); 156.8. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ - 5.16 and - 5.31. IR ν 515; 720; 789; 889; 969; 1030; 1259; 1393; 1465; 1757; 2852; 2921; 3387. HR-MS (ESI⁺) *m/z* [M-CI]⁺ calcd for C₄₃H₈₇NO₇P⁺ 760.6215, found 760.6221.

3-(((Erucyloxy)((oleoyloxy)methoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (E_{E18:1}**).** Compound **E_{E18:1}** (115 mg,

35 %) was obtained from erufosine (200 mg, 0.40 mmol) and chloromethyl oleate (1.05 g, 3.17 mmol) according to the general procedure. R_f : 0.65 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, $J_1 = 7.0$ Hz, 6H); 1.27 (m, 50H); 1.63 (tt, $J_1 = J_2 = 6.8$ Hz, 2H); 1.68 (tt, $J_1 = J_2 = 7.4$ Hz, 2H); 2.00 (m, 8H); 2.28 (m, 2H); 2.38 (t, $J = 7.5$ Hz, 2H); 3.48 (s, 9H); 3.81 (m, 2H); 4.07 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 4.23 (m, 2H); 5.34 (m, 4H); 5.62 (ABX syst., $J_{AB} = 4.8$ Hz, $J_{AX} = 12.7$ Hz, $J_{BX} = 10.9$ Hz, 2H). ¹³C-NMR δ (100.7 MHz, CDCl₃) δ 14.3 (2C); 22.9 (2C); 24.5 (C); 24.7 (C); 25.6; 27.4 (4C); 29.2; 29.3; 29.4; 29.5 (7C); 29.7 (5C); 29.8 (3C); 29.9 (2C); 30.4; 32.1 (2C); 34.2; 53.8 (3C); 63.7; 64.7; 69.1; 82.8; 129.8; 130.0; 130.1; 130.3; 172.4. ³¹P-NMR (162 MHz, CDCl₃) δ -3.42. IR ν 495; 721; 796; 844; 970; 1055; 1146; 1241; 1465; 1647; 1750; 2852; 2921; 3387. HR-MS (ESI+) m/z [M-Cl]⁺ calcd for C₄₇H₉₃NO₆P⁺ 798.6735, found 798.6739.

3-(((Erucyloxy)(1-(oleoyloxy)ethoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E_{E18:1}**). Compound **E_{E18:1}** (158 mg, 47 %) was obtained as two separated couples of enantiomers from erufosine (200 mg, 0.40 mmol) and 1-chloroethyl oleate (995 mg, 2.88 mmol) according to the general procedure. R_f : 0.7 (E1) and 0.65 (E2) (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) E1 δ 0.86 (t, $J = 7.0$ Hz, 6H); 1.25 (m, 50H); 1.55 (d, $J = 5.3$ Hz, 3H); 1.61 (tt, $J_1 = J_2 = 6.8$ Hz, 2H); 1.68 (tt, $J_1 = J_2 = 7.4$ Hz, 2H); 2.00 (m, 8H); 2.18 (m, 2H); 2.36 (t, $J = 7.4$ Hz, 2H); 3.18 (s, 9H); 3.52 (m, 2H); 4.04 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 4.16 (m, 2H); 5.31 (m, 4H); 6.44 (dq, $J_1 = J_2 = 5.3$ Hz, 1H). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) E2 δ 0.86 (t, $J = 7.0$ Hz, 6H); 1.25 (m, 50H); 1.55 (d, $J = 5.3$ Hz, 3H); 1.61 (tt, $J_1 = J_2 = 6.8$ Hz, 2H); 1.68 (tt, $J_1 = J_2 = 7.4$ Hz, 2H); 2.00 (m, 8H); 2.18 (m, 2H); 2.36 (t, $J = 7.4$ Hz, 2H); 3.18 (s, 9H); 3.52 (m, 2H); 4.04 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 4.16 (m, 2H); 5.31 (m, 4H); 6.45 (dq, $J_1 = J_2 = 5.3$ Hz, 1H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) E1 δ 14.5 (2C); 21.7; 23.3 (2C); 24.8; 25.3; 26.0; 27.8 (4C); 29.7; 29.8 (3C); 30.0 (3C); 30.2 (4C); 30.3 (5C); 30.4 (4C); 30.9; 32.6 (2C); 34.7; 53.7 (3C); 64.3; 65.2; 69.6; 92.0; 130.3; 130.5; 130.6; 130.7; 173.0. ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) E2 δ 14.5 (2C); 21.7; 23.3 (2C); 24.8; 25.1; 26.0; 27.8 (4C); 29.7; 29.8 (3C); 30.0 (3C); 30.2 (4C); 30.3 (5C); 30.4 (4C); 30.9; 32.6 (2C); 34.5; 53.7 (3C); 64.3; 65.2; 69.6; 92.0; 130.3; 130.5; 130.6; 130.7; 172.8. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ -5.16 (E1); -5.68 (E2). IR ν 516; 721; 849; 968; 1030; 1082; 1160; 1270; 1465; 1754; 2852; 2921; 3377. HR-MS (ESI+) m/z [M-Cl]⁺ calcd for C₄₈H₉₅NO₆P⁺ 812.6892, found 812.6883.

3-(((Erucyloxy)(((oleoyloxy)carbonyl)oxy)methoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E_{C18:1}**). Compound **E_{C18:1}** (200 mg, 58 %) was obtained from erufosine (200 mg, 0.40 mmol) and chloromethyl oleyl carbonate (1.16 g, 3.18 mmol) according to the general procedure. R_f : 0.65 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CDCl₃) δ 0.88 (t, $J = 6.6$ Hz, 6H); 1.26 (m, 52H); 1.68 (tt, $J_1 = J_2 = 6.8$ Hz, 4H); 2.00 (m, 8H); 2.29 (m, 2H); 3.49 (s, 9H); 3.78 (m, 2H); 4.07 (td, $J_1 = J_2 = 6.8$ Hz, 2H); 4.18 (t, $J = 6.8$ Hz, 2H); 4.21 (m, 2H); 5.34 (m, 4H); 5.63 (m, 2H). ¹³C-NMR δ (100.7 MHz, CDCl₃) δ 14.3 (2C); 22.9 (2C); 24.6; 25.4; 25.6; 27.4 (4C); 28.7; 29.4 (3C); 29.5 (4C); 29.6; 29.8 (4C); 29.9 (4C); 30.0 (4C); 30.3; 32.1 (2C); 53.7 (3C); 63.7; 64.7; 69.2; 69.5; 85.8; 129.9; 130.0; 130.1; 130.2; 153.1. ³¹P-NMR (162 MHz, CDCl₃) δ -3.03. IR ν 502; 721; 772; 858; 947; 1027; 1155; 1256; 1464; 1761; 2852; 2921; 3390. HR-MS (ESI+) m/z [M-Cl]⁺ calcd for C₄₈H₉₅NO₇P⁺ 828.6841, found 828.6837.

3-(((Erucyloxy)(1-(((oleoyloxy)carbonyl)oxy)ethoxy))phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E_{C18:1}**). Compound **E_{C18:1}** (169 mg, 49 %) was obtained as two separated couples of enantiomers from erufosine (199 mg, 0.40 mmol) and 1-chloroethyl oleyl carbonate (1.18 mg, 3.14 mmol) according to the general procedure. R_f : 0.7 (E1) and 0.6 (E2) (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CDCl₃) E1 δ 0.88 (t, $J = 6.6$ Hz, 6H); 1.26 (m, 52H); 1.58 (d, $J = 5.2$ Hz, 3H); 1.68 (tt, $J_1 = J_2 = 6.8$ Hz, 4H); 2.00 (m, 8H); 2.28 (m, 2H); 3.49 (s, 9H); 3.81 (m,

2H); 4.02-4.23 (m, 6H); 5.35 (m, 4H); 6.35 (qd, $J_1 = J_2 = 5.2$ Hz, 1H). ¹H-NMR (400 MHz, CDCl₃) E2 δ 0.88 (t, $J = 6.6$ Hz, 6H); 1.26 (m, 52H); 1.56 (d, $J = 5.2$ Hz, 3H); 1.67 (tt, $J_1 = J_2 = 6.8$ Hz, 4H); 2.00 (m, 8H); 2.28 (m, 2H); 3.49 (s, 9H); 3.81 (m, 2H); 4.02-4.23 (m, 6H); 5.33 (m, 4H); 6.41 (qd, $J_1 = J_2 = 5.2$ Hz, 1H). ¹³C-NMR δ (100.7 MHz, CDCl₃) E1 δ 14.3 (2C); 21.6; 22.8 (2C); 24.5; 25.5; 25.8; 27.4 (4C); 28.7; 29.3; 29.4 (2C); 29.5 (6C); 29.6 (3C); 29.7 (2C); 29.8 (3C); 29.9 (3C); 30.1; 31.9 (2C); 53.7 (3C); 63.7; 64.3; 68.9; 69.2; 94.7; 129.9; 130.0; 130.1; 130.2; 153.5. ¹³C-NMR δ (100.7 MHz, CDCl₃) E2 δ 14.3 (2C); 21.6; 22.8 (2C); 24.5; 25.5; 25.8; 27.4 (4C); 28.8; 29.4 (3C); 29.5 (6C); 29.6 (3C); 29.7 (5C); 29.9 (3C); 30.1; 31.9 (2C); 53.7 (3C); 63.7; 64.3; 69.1 (2C); 94.6; 129.9; 130.0; 130.1; 130.2; 153.3. ³¹P-NMR (162 MHz, CDCl₃) δ -5.00 (E1); -5.71 (E2). IR ν 512; 721; 787; 887; 969; 1032; 1259; 1392; 1465; 1757; 2852; 2921; 3379. HR-MS (ESI+) m/z [M-Cl]⁺ calcd for C₄₉H₉₇NO₇P⁺ 842.6997, found 842.7005 (E1) and 842.7001 (E2).

3-(((Acetyloxy)methoxy)(erucyloxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E_{E2}**). Compound **E_{E2}** (8 mg, 6 %) was obtained from erufosine (120 mg, 0.24 mmol) and chloromethyl acetate (215 mg, 1.91 mmol) according to the general procedure. R_f : 0.15 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.85 (t, $J = 6.8$ Hz, 3H); 1.25 (m, 30H); 1.68 (tt, $J_1 = J_2 = 7.2$ Hz, 2H); 2.01 (m, 4H); 2.14 (s, 3H); 2.19 (m, 2H); 3.17 (s, 9H); 3.49 (m, 2H); 4.07 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 4.18 (m, 2H); 5.31 (m, 2H); 5.60 (ABX syst., $J_{AB} = 5.6$ Hz, $J_{AX} = 13.4$ Hz, $J_{BX} = 12.2$ Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.5; 20.9; 23.2; 24.8; 26.0; 27.8 (2C); 29.9; 30.0 (2C); 30.2 (3C); 30.3 (4C); 30.4 (2C); 30.9; 32.6; 53.7 (3C); 64.3; 65.5; 69.8; 83.4; 130.5 (2C); 171.8. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ -3.43. IR ν 671; 975; 1033; 1120; 1463; 1767; 2852; 2922; 3366. HR-MS (ESI+) m/z [M-Cl]⁺ calcd for C₃₁H₆₃NO₆P⁺ 576.4388, found 576.4390.

3-(((Erucyloxy)(((hexanoyloxy)methoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E_{E6}**). Compound **E_{E6}** (47 mg, 30 %) was obtained from erufosine (120 mg, 0.24 mmol) and chloromethyl hexanoate (315 mg, 1.89 mmol) according to the general procedure. R_f : 0.3 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.85 (t, $J = 6.8$ Hz, 3H); 0.88 (t, $J = 6.6$ Hz, 3H); 1.25 (m, 34H); 1.63 (tt, $J_1 = J_2 = 6.8$ Hz, 2H); 1.68 (tt, $J_1 = J_2 = 7.2$ Hz, 2H); 2.01 (m, 4H); 2.19 (m, 2H); 2.41 (t, $J = 7.5$ Hz, 2H); 3.17 (s, 9H); 3.49 (m, 2H); 4.09 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 4.20 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 5.30 (m, 2H); 5.63 (ABX syst., $J_{AB} = 5.2$ Hz, $J_{AX} = 13.5$ Hz, $J_{BX} = 11.7$ Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.2; 14.4; 22.8; 23.2; 24.6; 24.7; 25.9; 27.7 (2C); 29.7; 29.8 (3C); 30.0 (3C); 30.1; 30.2 (2C); 30.3 (2C); 30.8; 31.7; 32.4; 34.3; 53.7 (3C); 64.1; 65.2; 69.7; 83.2; 130.4 (2C); 173.0. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ -3.41. IR ν 493; 755; 857; 970; 1028; 1157; 1269; 1465; 1760; 2852; 2922; 3372. HR-MS (ESI+) m/z [M-Cl]⁺ calcd for C₃₅H₇₁NO₆P⁺ 632.5014, found 632.5009.

3-(((Erucyloxy)(((octanoyloxy)methoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E_{E8}**). Compound **E_{E8}** (192 mg, 69 %) was obtained from erufosine (202 mg, 0.40 mmol) and chloromethyl octanoate (620 mg, 3.22 mmol) according to the general procedure. R_f : 0.35 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.86 (t, $J = 6.8$ Hz, 6H); 1.26 (m, 38H); 1.63 (tt, $J_1 = J_2 = 6.8$ Hz, 2H); 1.68 (tt, $J_1 = J_2 = 7.4$ Hz, 2H); 2.01 (m, 4H); 2.19 (m, 2H); 2.41 (t, $J = 7.5$ Hz, 2H); 3.17 (s, 9H); 3.49 (m, 2H); 4.09 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 4.20 (td, $J_1 = J_2 = 6.9$ Hz, 2H); 5.32 (m, 2H); 5.63 (ABX syst., $J_{AB} = 5.2$ Hz, $J_{AX} = 13.8$ Hz, $J_{BX} = 11.1$ Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.4; 14.5; 23.2; 23.3; 24.7; 25.2; 26.1; 27.8 (2C); 29.7 (2C); 29.9; 30.0 (3C); 30.2 (3C); 30.3 (3C); 30.4 (2C); 30.9; 32.4; 32.6; 34.5; 53.7 (3C); 64.3; 65.5; 69.9; 83.4; 130.5; 130.6; 173.2. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ -3.50. IR ν 506; 756; 858; 970; 1028; 1152; 1269; 1466; 1760; 2852; 2922; 3384. HR-MS (ESI+) m/z [M-Cl]⁺ calcd for C₃₇H₇₅NO₆P⁺ 660.5327, found 660.5317.

3-(((Decanoyloxy)methoxy)(erucyloxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E10**). Compound **E10** (220 mg, 74 %) was obtained from erufosine (206 mg, 0.41 mmol) and chloromethyl decanoate (716 mg, 3.27 mmol) according to the general procedure. *R*_f: 0.45 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.86 (t, *J* = 6.8 Hz, 6H); 1.25 (m, 42H); 1.63 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 1.68 (tt, *J*₁ = *J*₂ = 7.4 Hz, 2H); 2.01 (m, 4H); 2.19 (m, 2H); 2.41 (t, *J* = 7.5 Hz, 2H); 3.17 (s, 9H); 3.49 (m, 2H); 4.09 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 4.20 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 5.32 (m, 2H); 5.63 (ABX syst., *J*_{AB} = 5.2 Hz, *J*_{AX} = 13.8 Hz, *J*_{BX} = 11.1 Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.6 (2C); 23.6 (2C); 25.1; 25.5; 26.4; 28.1 (2C); 30.0; 30.2 (3C); 30.3 (3C); 30.4 (2C); 30.5 (2C); 30.6 (3C); 30.7 (2C); 31.2; 32.9 (2C); 34.8; 53.9 (3C); 64.5; 66.0; 70.1; 83.8; 130.8 (2C); 173.6. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ - 3.17. IR ν 512; 752; 787; 858; 970; 1027; 1149; 1273; 1466; 1761; 2852; 2922; 3373. HR-MS (ESI+) *m/z* [M-Cl]⁺ calcd for C₃₉H₇₉NO₆P⁺ 688.5640, found 688.5632.

3-(((Erucyloxy)((tetradecanoyloxy)methoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E14**). Compound **E14** (100 mg, 32 %) was obtained from erufosine (200 mg, 0.40 mmol) and chloromethyl tetradecanoate (890 mg, 3.21 mmol) according to the general procedure. *R*_f: 0.5 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.86 (t, *J* = 6.8 Hz, 6H); 1.25 (m, 50H); 1.63 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 1.68 (tt, *J*₁ = *J*₂ = 7.4 Hz, 2H); 2.01 (m, 4H); 2.19 (m, 2H); 2.41 (t, *J* = 7.5 Hz, 2H); 3.17 (s, 9H); 3.49 (m, 2H); 4.09 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 4.20 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 5.32 (m, 2H); 5.63 (ABX syst., *J*_{AB} = 5.2 Hz, *J*_{AX} = 13.8 Hz, *J*_{BX} = 11.1 Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.5 (2C); 23.4 (2C); 24.9; 25.3; 26.2; 27.9 (2C); 29.8; 29.9; 30.0 (2C); 30.1 (2C); 30.3 (4C); 30.6 (8C); 30.5 (2C); 31.0; 32.7 (2C); 34.6; 53.7 (3C); 64.3; 65.6; 70.0; 83.5; 130.6 (2C); 173.3. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ - 3.29. IR ν 515; 721; 772; 859; 966; 1030; 1160; 1269; 1467; 1760; 2849; 2918; 2956; 3395. HR-MS (ESI+) *m/z* [M-Cl]⁺ calcd for C₄₃H₈₇NO₆P⁺ 744.6266, found 744.6259.

3-(((Erucyloxy)((hexadecanoyloxy)methoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E16**). Compound **E16** (237 mg, 74 %) was obtained from erufosine (200 mg, 0.40 mmol) and chloromethyl hexadecanoate (980 mg, 3.21 mmol) according to the general procedure. *R*_f: 0.45 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.86 (t, *J* = 6.8 Hz, 6H); 1.24 (m, 54H); 1.63 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 1.68 (tt, *J*₁ = *J*₂ = 7.4 Hz, 2H); 2.01 (m, 4H); 2.19 (m, 2H); 2.41 (t, *J* = 7.5 Hz, 2H); 3.17 (s, 9H); 3.49 (m, 2H); 4.09 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 4.20 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 5.32 (m, 2H); 5.63 (ABX syst., *J*_{AB} = 5.2 Hz, *J*_{AX} = 13.8 Hz, *J*_{BX} = 11.1 Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.5 (2C); 23.3 (2C); 24.8; 25.2; 26.1; 27.8 (2C); 29.7; 29.8; 30.0 (6C); 30.2 (4C); 30.3 (8C); 30.4 (2C); 30.9; 32.6 (2C); 34.5; 53.7 (3C); 64.3; 65.4; 69.9; 83.4; 130.5 (2C); 173.2. ³¹P-NMR (162 MHz, CD₃OD/CDCl₃ 1:1) δ - 3.34. IR ν 506; 720; 758; 859; 969; 1021; 1159; 1272; 1467; 1760; 2850; 2918; 3379. HR-MS (ESI+) *m/z* [M-Cl]⁺ calcd for C₄₅H₉₁NO₆P⁺ 772.6579, found 772.6569.

3-(((Erucyloxy)((octadecanoyloxy)methoxy)phosphoryl)oxy)-N,N,N-trimethylpropan-1-aminium chloride (**E18**). Compound **E18** (91 mg, 55 %) was obtained from erufosine (100 mg, 0.20 mmol) and chloromethyl octadecanoate (530 mg, 1.59 mmol) according to the general procedure. *R*_f: 0.5 (CH₂Cl₂/MeOH/H₂O 75:22:3). ¹H-NMR (400 MHz, CD₃OD/CDCl₃ 1:1) δ 0.88 (t, *J* = 6.8 Hz, 6H); 1.24 (m, 58H); 1.62 (tt, *J*₁ = *J*₂ = 6.8 Hz, 2H); 1.68 (tt, *J*₁ = *J*₂ = 7.4 Hz, 2H); 2.00 (m, 4H); 2.28 (m, 2H); 2.38 (t, *J* = 7.5 Hz, 2H); 3.47 (s, 9H); 3.80 (m, 2H); 4.05 (td, *J*₁ = *J*₂ = 6.9 Hz, 2H); 4.23 (m, 2H); 5.34 (m, 2H); 5.63 (ABX syst., *J*_{AB} = 4.8 Hz, *J*_{AX} = 12.9 Hz, *J*_{BX} = 11.1 Hz, 2H). ¹³C-NMR δ (100.7 MHz, CD₃OD/CDCl₃ 1:1) δ 14.3 (2C); 22.8 (2C); 24.5; 24.7; 25.5; 27.4 (2C); 29.2; 29.3; 29.4; 29.5 (4C); 29.7 (3C); 29.8 (6C); 29.9 (6C); 30.0 (2C); 30.4; 32.0 (2C); 34.1; 53.8 (3C); 63.7; 64.6; 69.1; 82.7; 130.0 (2C); 172.4. ³¹P-NMR (162 MHz,

CD₃OD/CDCl₃ 1:1) δ - 3.29. IR ν 508; 721; 771; 859; 967; 1032; 1161; 1267; 1467; 1761; 2849; 2917; 3377. HR-MS (ESI+) *m/z* [M-Cl]⁺ calcd for C₄₇H₉₅NO₆P⁺ 800.6892, found 800.6891.

Methods

Nucleic acid retardation assay. Freshly prepared lipoplexes (*vide infra*) at the desired N/P ratio (where N is the concentration of the lipid ammonium group and P that of nucleic acid phosphate) were analyzed by electrophoresis through a 1 % agarose gel. The gel was run in a 40 mM Tris-acetate-EDTA buffer, pH 8.0 and nucleic acid was further stained using an ethidium bromide solution (0.5 μg/mL).

Dynamic light scattering (DLS) measurements. The average particle size and zeta potential of lipoplexes were measured using a Zetasizer nanoZS apparatus (Malvern Instruments, Paris, France). All measurements were performed on freshly prepared lipoplexes (*vide infra*) at 25 °C and in triplicate. Data were analyzed using the multimodal number distribution software supplied with the instrument and expressed as mean (± SD).

Erufosine prodrug hydrolytic stability determination. Hydrolysis rate of pro-APLs was measured by ³¹P-NMR spectroscopy. Compounds were formulated as liposomes using a solvent injection technique.^[23] Briefly, the pro-APLs (10 μmol) were dissolved in *i*-PrOH (200 μL) and then injected with a syringe at a flow rate of approximately 600 μL min⁻¹ and a stirring speed of 400 rpm into the appropriate aqueous buffer medium (300 μL, either HEPES 10 mM pH 7.4, or AcOK/AcOH 10 mM pH 4.5) containing 10 mM Triton X-100. The resulting preparations were complemented with buffer (400 μL) and D₂O (100 μL) and introduced into 5-mm NMR tubes, and ³¹P-NMR spectra were recorded periodically at 20 °C with a 4-s pulse cycle for quantitative measurements.

Pro-APLs self-assembly studies. Self-assembly properties of erufosine and pro-APLs were determined using a fluorescent probe technique.^[15] A lipid film obtained by evaporation in a SpeedVac apparatus for 1 h of the adequate volume of an ethanolic solution (2 mM) of the selected compound was dispersed in H₂O (2 mM) and diluted in a concentration range from 2 mM to 2 nM. Pyrene (0.1 mM in DMSO, 10 μL) was added to the samples under vigorous stirring, and the mixtures were incubated in the dark for 30 min at 25 °C. Fluorescence spectra were then recorded at 350 to 450 nm with excitation at 330 nm, with a Fluoromax-4 spectrophotometer (Horiba Jobin Yvon). Emission spectral ratio at 375 and 387 nm (*I*₃₇₅/*I*₃₈₇) was expressed as the logarithm of concentration, and the concentration above which the molecules spontaneously associate to form micelles or aggregates was graphically determined as the first break point in the fluorescence behavior of pyrene.

Hemolytic activity determination. Red blood cell (RBC) leakage assay was carried out according to a procedure described elsewhere.^[52] RBC were prepared from defibrinated sheep blood. Briefly, blood sample (5 mL) was centrifuged at 500 x g for 5 min. After removal of the yellow upper layer, an equal volume of PBS pH 7.4 was added to the sample, and the mixture was homogenized. This treatment (centrifugation, removal of upper layer, addition of PBS and homogenization) was repeated three times. The last homogenate was diluted to 1/25 in PBS and the resulting suspension of RBCs (140 μL) was added to lipid samples (*vide supra*, 10 μL) prepared at increasing concentration (from 45 μM to 3 mM) in 96-well plates. After incubation for 1 or 24 h at 37 °C and 5 % CO₂, plates were centrifuged at 250 x g for 10 min to pellet intact RBC and absorbance of the supernatants (100 μL) was measured at 450 nm. Hemolysis induced by the compounds was expressed as percent, calculated from negative and 100% controls, and plotted as a function of lipid concentration. Negative control was obtained on suspensions of RBC in PBS alone. Complete hemolysis

(100 % control) was obtained by adding Triton X-100® (10 µM, 10 µL) to suspensions of RBC in PBS alone. Lipid concentrations inducing 50 % hemolysis (HC₅₀) and the percentage of hemolysis provoked by 200 µM of the lipids (HA₂₀₀) were graphically determined from the curve fitted to the data.

Cell culture. All cell lines were grown in culture flasks (Becton-Dickinson) at 37 °C in a 5 % CO₂ humidified chamber. Human lung carcinoma (A549) and bronchial (16HBE) epithelial cells were grown in DMEM/F12 medium containing FBS (10 %), penicillin (100 units/mL), streptomycin (100 µg/mL), and Hepes (5 mM). Lung mucoepidermoid carcinoma cells (H292) were grown in RPMI 1640 supplemented with FBS (10 %), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 units/mL), streptomycin (100 µg/mL), and Hepes (10 mM). At confluence, cells were released from flasks with trypsin (0.5 % in PBS), centrifuged (4 °C, 5 min, 120 g) counted and transferred into 96-well plates (Becton-Dickinson) in 100 µL culture medium (A549: 6,000 cells/well; H292: 9,000 cells/well; 16HBE: 12,000 cells/well) for transfection experiments, cytotoxicity assays, or IC₅₀ determinations. Plates were maintained at 37 °C in a 5 % CO₂ humidified chamber for 24 h before experiment.

Preparation of lipoplexes. Typically, the appropriate volume of a freshly prepared solution of pro-erufosine compound (2 mM in EtOH) was deposited at the bottom of a 500 µL polyethylene tube and dried under vacuum for 1 h. Then, pCMV-Gluc DNA (40 µL at the required concentration in 5 % glucose, DNA concentration refers to phosphate content) was added to the resulting lipid film. After stirring by vortex for 20 s, the preparation was allowed to stand at rt for 30 min before use.

Transfection experiments. Cells were seeded into 96-well plates (Becton-Dickinson) at the required density (*vide supra*) in 100 µL of serum containing culture medium. Twenty-four hours later, freshly prepared DNA lipoplexes (10 µL, *i.e.* 0.4 µg DNA) were added to the wells and cells were then let to grow in the incubator without further handling for 24 h. Negative control was obtained by adding glucose 5 % (10 µL) to the wells instead of lipoplexes. Then, *Gaussia* luciferase production was measured by monitoring light production on an aliquot of culture supernatant (20 µL of a 1/100th dilution of supernatant prepared in non-supplemented culture medium) for 1 sec upon addition of the coelenterazine substrate (50 µL, 1.5 µM) using a luminometer (Berthold Centro LB960 XS, Thoiry, France). Protein content of the culture supernatant was determined using a bicinchoninic acid (BCA) assay and luciferase activity was normalized to protein content (RLU/mg protein). Value for each sample is the mean of a triplicate determination (± SD).

Cytotoxicity assay. Mitochondrial activity measurements (MTT assay) was used to assess cytotoxicity of the compounds. Lipid samples were prepared from a lipid film (3.6 µmol of compound evaporated from an ethanolic solution) hydrated with aqueous glucose 5 % and vigorously vortexed for 20 s before serial dilution in aqueous glucose 5 %. Part of the culture medium in the plates prepared the day before (25 µL) was removed and replaced by lipid samples (25 µL). Negative control was obtained by adding glucose 5 % to the cells instead of lipoplexes. After a 24-h incubation period at 37 °C, culture supernatant was removed, cells were carefully washed with PBS and 0.5 mg/mL MTT (100 µL) in complete culture medium was added. After a 1-h incubation period at 37 °C, MTT solution was removed and DMSO (100 µL) was added to lyse cells and dissolve reduced MTT. Intensity of MTT reduction was then evaluated by measuring absorbance at 492 nm. Viability of cells treated with lipids or lipoplexes was expressed as the percentage of the absorbance measured in untreated cells. Value for each sample is the mean of triplicate determinations (±SD). IC₅₀ values were determined within the 95 % confidence interval using nonlinear regression analysis with the GraphPad Prism software (GraphPad Software, San Diego, CA, USA).

Analysis of cell TRAIL receptor expression and sensitivity. To assess TRAIL expression, A549, H292, and 16HBE cells (10⁶ cells) were washed with PBS containing 2 % FCS and incubated for 4 h at 4 °C with a PE-labeled monoclonal antibody targeting TRAIL-R1, R2, R3, or R4 according to concentration recommended by the manufacturer. After two washes with PBS-2 % FCS, TRAIL receptor expression was monitored by flow cytometry (Guava EasyCyte™, Merck Milipore, Darmstadt, Germany) and data were analyzed with InCyte Software (Merck Milipore).

For determination of cell sensitivity to TRAIL, A549, H292, and 16HBE cells were washed with PBS containing 2 % FCS and incubated for 4 h in 96-well plates (30,000 cells, 100 µL) before addition of increasing amounts (in 10 µL) of SPK. After 24 h incubation at 37 °C, cell viability was determined by MTT assay as described above.

Statistical analysis. All data are presented as the mean ± standard deviation (SD). Statistical significance between treatments was assessed by one-way analysis of variance (ANOVA) followed by the Dunnett multiple comparison test, using the Kaleidagraph 4.5 software (Synergy Software, Reading, PA, USA). Data were considered as statistically significant for *p* value less than 0.05 (***) *p* < 0.001, ** *p* < 0.01, * *p* < 0.05.

Acknowledgements

The authors are grateful for financial support to BG from Labex Medalis, Région Alsace, and Alsace contre le Cancer.

Keywords: erufosine • prodrug • gene therapy • chemotherapy • hemolytic toxicity

- [1] a) J. de Almeida Pachioni, J. G. Magalhães, E. J. C. Lima, L. de Moura Bueno, J. F. Barbosa, M. M. de Sá and C. O. Rangel-Yaguí, *J. Pharm. Pharm. Sci.* **2013**, *16*, 742-759; b) P.-A. Jaffrès, C. Gajate, A. M. Bouchet, H. Couthon-Gourvès, A. Chantôme, M. Potier-Cartreau, P. Besson, P. Bougnoux, F. Mollinedo and C. Vandier, *Pharmacol. Ther.* **2016**, *165*, 114-131; c) P. Rios-Marco, C. Marco, X. Gálvez, J. M. Jiménez-López and M. P. Carrasco, *Biochim. Biophys. Acta-Biomembr.* **2017**, *1859*, 1657-1667.
- [2] A. Kostadinova, T. Topouzova-Hristova, A. Momchilova, R. Tzoneva and M. R. Berger in *Advances in Protein Chemistry and Structural Biology, Vol. 101* (Ed. R. Donev), **2015**, pp. 27-66.
- [3] H. Eibl, D. Arnold, H. U. Weltzien and O. Westphal, *Liebigs Ann. Chem.* **1967**, *709*, 226-230.
- [4] C. Gajate and F. Mollinedo, *Curr. Drug Metab.* **2002**, *3*, 491-525.
- [5] a) R. Andreesen, M. Modolell, H. U. Weltzien, H. Eibl, H. H. Common, G. W. Löhr and P. G. Munder, *Cancer Res.* **1978**, *38*, 3894-3899; b) P. G. Munder, M. Modolell, R. Andreesen, H. U. Weltzien and O. Westphal, *Springer Semin. Immunopathol.* **1979**, *2*, 187-203.
- [6] D. Berkovic, *Gen. Pharmacol.* **1998**, *31*, 511-517.
- [7] P. Hilgard, T. Klenner, J. Stekar, G. Nössner, B. Kutscher and J. Engel, *Eur. J. Cancer* **1997**, *33*, 442-446.
- [8] S. R. Vink, J. H. M. Schellens, W. J. van Blitterswijk and M. Verheij, *Invest. New Drugs* **2005**, *23*, 279-286.
- [9] P. G. Richardson, C. Eng, J. Kolesar, T. Hideshima and K. C. Anderson, *Expert Opin. Drug Metab. Toxicol.* **2012**, *8*, 623-633.
- [10] J. Köting, M. R. Berger, C. Unger and H. Eibl, *Cancer Chemother. Pharmacol.* **1992**, *30*, 105-112.
- [11] R. G. Bagley, L. Kurtzberg, C. Rouleau, M. Yao and B. A. Teicher, *Cancer Chemother. Pharmacol.* **2011**, *68*, 1537-1546.
- [12] a) J. C. Bendell, J. Nemunaitis, S. J. Vukelja, C. Hagenstad, L. T. Campos, R. C. Hermann, P. Sportelli, L. Gardner and D. A. Richards, *J. Clin. Oncol.* **2011**, *29*, 4394-4400; b) S. Fu, B. T. Hennessy, C. S. Ng, Z. Ju, K. R. Coombes, J. K. Wolf, A. K. Sood, C. F. Levenback, R. L. Coleman, J. J. Kavanagh, D. M. Gershenson, M. Markman, K. Dice, A. Howard, J. Li, Y. Li, K. Stemke-Hale, M. Dyer, E. Atkinson, E. Jackson, V. Kundra, R. Kurzrock, R. C. Bast and G. B. Mills, *Gynecol. Oncol.* **2012**, *126*, 47-53; c) I. Gojo, A. Perl, S. Luger, M. R. Baer, K. J. Norsworthy, K. S. Bauer, M. Tidwell, S. Fleckinger, M. Carroll and E. A.

- Sausville, *Invest. New Drugs* **2013**, *31*, 1217-1227; d) A. Guidetti, C. Carlo-Stella, S. L. Locatelli, W. Malorni, R. Mortarini, S. Viviani, D. Russo, A. Marchiano, R. Sorasio, A. Dodero, L. Farina, L. Giordano, M. Di Nicola, A. Anichini, P. Corradini and A. M. Gianni, *Clin. Cancer Res.* **2014**, *20*, 5641-5651; e) P. G. Richardson, J. Wolf, A. Jakubowiak, J. Zonder, S. Lonial, D. Irwin, J. Densmore, A. Krishnan, N. Raju, M. Bar, T. Martin, R. Schlossman, I. M. Ghobrial, N. Munshi, J. Laubach, J. Allerton, T. Hideshima, K. Colson, E. Poradosu, L. Gardner, P. Sportelli and K. C. Anderson, *J. Clin. Oncol.* **2011**, *29*, 4243-4249.
- [13] a) C. Belka, V. Jendrossek, M. Pruschy, S. Vink, M. Verheij and W. Budach, *Int. J. Radiat. Oncol. Biol. Phys.* **2004**, *58*, 542-554; b) S. R. Vink, W. J. van Blitterswijk, J. H. M. Schellens and M. Verheij, *Cancer Treat. Rev.* **2007**, *33*, 191-202.
- [14] R. Zeisig, A. Ressa, I. Fichtner and W. Walther, *Cancer Gene Ther.* **2003**, *10*, 302-311.
- [15] N. Settelen, O. Roch, D. Bock, R. Rooke, S. Braun and O. Meyer, *J. Control. Release* **2004**, *94*, 237-244.
- [16] H. A. Elrod, Y.-D. Lin, P. Yue, X. Wang, S. Lonial, F. R. Khuri and S.-Y. Sun, *Mol. Cancer Ther.* **2007**, *6*, 2029-2038.
- [17] Z. U. Rehman, I. S. Zuhorn and D. Hoekstra, *J. Control. Release* **2013**, *166*, 46-56.
- [18] S. Mukherjee, T. T. Soe and F. R. Maxfield, *J. Cell Biol.* **1999**, *144*, 1271-1284.
- [19] R. L. Juliano, *Nucl. Acid Ther.* **2018**, *28*, 3.
- [20] B. Gaillard, J.-S. Remy, F. Pons and L. Lebeau, **submitted**.
- [21] M. C. Georgieva, S. M. Konstantinov, M. Topashka-Ancheva and M. R. Berger, *Cancer Lett.* **2002**, *182*, 163-174.
- [22] a) P. Pierrat, A. Casset, P. Didier, D. Kereselidze, M. Lux, F. Pons and L. Lebeau, *ChemBioChem* **2016**, *17*, 1771-1783; b) P. Pierrat, A. Casset, D. Kereselidze, M. Lux, F. Pons and L. Lebeau, *Macromol. Biosci.* **2016**, *16*, 984-989; c) P. Pierrat, G. Creusat, G. Laverny, F. Pons, G. Zuber and L. Lebeau, *Chem. Eur. J.* **2012**, *18*, 3835-3839; d) P. Pierrat, D. Kereselidze, M. Lux, L. Lebeau and F. Pons, *Int. J. Pharm.* **2016**, *511*, 205-218; e) P. Pierrat, D. Kereselidze, P. Wehrung, G. Zuber, F. Pons and L. Lebeau, *Pharm. Res.* **2013**, *30*, 1362-1379; f) P. Pierrat, G. Laverny, G. Creusat, P. Wehrung, J.-M. Strub, A. VanDorselaer, F. Pons, G. Zuber and L. Lebeau, *Chem. Eur. J.* **2013**, *19*, 2344-2355.
- [23] P. Gentine, A. Bubel, C. Crucifix, L. Bourel-Bonnet and B. Frisch, *J. Liposome Res.* **2012**, *22*, 18-30.
- [24] N. Dan and D. Danino, *Adv. Colloid Interface Sci.* **2014**, *205*, 230-239.
- [25] I. S. Zuhorn, U. Bakowsky, E. Polushkin, W. H. Visser, M. C. A. Stuart, J. Engberts and D. Hoekstra, *Mol. Ther.* **2005**, *11*, 801-810.
- [26] J. Rejman, V. Oberle, I. S. Zuhorn and D. Hoekstra, *Biochem. J.* **2004**, *377*, 159-169.
- [27] S. Audouy, G. Molema, L. de Leij and D. Hoekstra, *J. Gene Med.* **2000**, *2*, 465-476.
- [28] S. E. Han, H. Kang, G. Y. Shim, M. S. Suh, S. J. Kim, J. S. Kim and Y. K. Oh, *Int. J. Pharm.* **2008**, *353*, 260-269.
- [29] a) C. L. Chan, K. K. Ewert, R. N. Majzoub, Y. K. Hwu, K. S. Liang, C. Leal and C. R. Safinya, *J. Gene Med.* **2014**, *16*, 84-96; b) O. Zelphati, L. S. Uyechi, L. G. Barron and F. C. Szoka, *Biochim. Biophys. Acta* **1998**, *1390*, 119-133; c) L. Li, H. M. Song, K. Luo, B. He, Y. Nie, Y. Yang, Y. Wu and Z. W. Gu, *Int. J. Pharm.* **2011**, *408*, 183-190.
- [30] a) J. Kötting, N. W. Marschner, W. Neumüller, C. Unger and H. Eibl, *Prog. Exp. Tumor Res.* **1992**, *34*, 131-142; b) E. A. M. Fleer, D. Berkovic, C. Unger and H. Eibl, *Prog. Exp. Tumor Res.* **1992**, *34*, 33-46.
- [31] M. C. Parlato, J. P. Jee, M. Teshite and S. Mecozzi, *J. Org. Chem.* **2011**, *76*, 6584-6591.
- [32] a) H. Eibl and P. Kaufmann-Kolle, *J. Liposome Res.* **1995**, *5*, 131-148; b) F. Schuettauf, K. H. Eibl, S. Thaler, K. Shinoda, R. Rejda, C. A. May, G. Blatsios and U. Welge-Lüssen, *Curr. Eye Res.* **2005**, *30*, 813-820.
- [33] M. Lukac, M. Mrva, M. Garajova, G. Mojzisova, L. Varinska, J. Mojzis, M. Sabol, J. Kubincova, H. Haragova, F. Ondriska and F. Devinsky, *Eur. J. Med. Chem.* **2013**, *66*, 46-55.
- [34] a) I. Fichtner, R. Zeisig, H. Naundorf, S. Jungmann, D. Arndt, G. Asongwe, J. A. Double and M. C. Bibby, *Breast Cancer Res. Treat.* **1994**, *32*, 269-279; b) P. Kaufmann-Kolle, J. Dreves, M. R. Berger, J. Kotting, N. Marschner, C. Unger and H. Eibl, *Cancer Chemother. Pharmacol.* **1994**, *34*, 393-398.
- [35] R. Zeisig, S. Jungmann, D. Arndt, A. Schutt and E. Nissen, *Anti-Cancer Drugs* **1993**, *4*, 57-64.
- [36] T. Mosmann, *J. Immunol. Methods* **1983**, *65*, 55-63.
- [37] J. M. W. Gee, A. Howell, W. J. Gullick, C. C. Benz, R. L. Sutherland, R. J. Santen, L. A. Martin, F. Ciardiello, W. R. Miller, M. Dowsett, P. Barrett-Lee, J. F. R. Robertson, S. R. Johnston, H. E. Jones, A. E. Wakeling, R. Duncan and R. I. Nicholson, *Endocr.-Relat. Cancer* **2005**, *12*, S1-S7.
- [38] H. J. Lee, G. L. Zhuang, Y. Cao, P. Du, H. J. Kim and J. Settleman, *Cancer Cell* **2014**, *26*, 207-221.
- [39] W. Huang, L. Q. Chen, L. Kang, M. J. Jin, P. Sun, X. Xin, Z. G. Gao and Y. H. Bae, *Adv. Drug Deliv. Rev.* **2017**, *115*, 82-97.
- [40] V. Tsouris, M. K. Joo, S. H. Kim, I. C. Kwon and Y. Y. Won, *Biotechnol. Adv.* **2014**, *32*, 1037-1050.
- [41] Y. S. Shi, X. Pang, J. Q. Wang and G. Liu, *Adv. Healthc. Mater.* **2018**, *7*, 15.
- [42] D. Merino, N. Lalaoui, A. Morizot, P. Schneider, E. Solary and O. Micheau, *Mol. Cell. Biol.* **2006**, *26*, 7046-7055.
- [43] S. Shirley, A. Morizot and O. Micheau, *Recent Patents Anti-Canc. Drug Discov.* **2011**, *6*, 311-323.
- [44] N. Chekka, C. M. Lombardo, C. Seguin, M.-C. Lechner, F. Dufour, Y. Nominé, M. De Giorgi, B. Frisch, O. Micheau, G. Guichard, D. Altschuh and S. Fournel, *Oncotarget* **2018**, *9*, 15566.
- [45] K. Azijli, I. A. M. van Roosmalen, J. Smit, S. Pillai, M. Fukushima, S. de Jong, G. J. Peters, I. V. Bijnisdorp and F. A. E. Kruyt, *Cancer Chemother. Pharmacol.* **2014**, *73*, 1273-1283.
- [46] P. M. Nair, H. Flores, A. Gogineni, S. Marsters, D. A. Lawrence, R. F. Kelley, H. Ngu, M. Sagolla, L. Komuves, R. Bourgon, J. Settleman and A. Ashkenazi, *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112*, 5679-5684.
- [47] L. D. Mayer and A. S. Janoff, *Mol. Interv.* **2007**, *7*, 216-223.
- [48] L. Lebeau, S. Olland, P. Oudet and C. Mioskowski, *Chem. Phys. Lipids* **1992**, *62*, 93-103.
- [49] M. Kim, A. Pitchaiah, N.-J. Park, I. T. Hwang and K.-I. Lee, *Lett. Org. Chem.* **2012**, *9*, 628-631.
- [50] J. A. Heyes, D. Niculescu-Duvaz, R. G. Cooper and C. J. Springer, *J. Med. Chem.* **2002**, *45*, 99-114.
- [51] a) E. D. Goddard, N. J. Turro, P. L. Kuo and K. P. Ananthapadmanabhan, *Langmuir* **1985**, *1*, 352-355; b) L. Piñeiro, M. Novo and W. Al-Soufi, *Adv. Colloid Interface Sci.* **2015**, *215*, 1-12.
- [52] B. C. Evans, C. E. Nelson, S. S. Yu, K. R. Beavers, A. J. Kim, H. Li, H. M. Nelson, T. D. Giorgio and C. L. Duvall, *J. Vis. Exp.* **2013**, *73*, e50166.

FULL PAPER

Entry for the Table of Contents (Please choose one layout)

Layout 1:

FULL PAPER

Text for Table of Contents

Author(s), Corresponding Author(s)*


Page No. – Page No.

Title

((Insert TOC Graphic here: max. width: 5.5 cm; max. height: 5.0 cm))

Layout 2:

FULL PAPER



Boris Gaillard, Cendrine Seguin, Jean-Serge Remy, Françoise Pons, Luc Lebeau*

Page No. – Page No.

Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy

Dual erufosine prodrugs: Biolabile cationic derivatives of the antiproliferative alkylphospholipid erufosine have been synthesized and show combined antitumor activity with a plasmid encoding the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with selectivity for tumor vs. non-tumor cells.